

07/01  
4 October 2000



## **DRAFT RISK ANALYSIS REPORT**

### **APPLICATION A386**

### **Food derived from insect-protected, herbicide-tolerant Bt-11 corn**

**Note:**

This report is the “Full Assessment” as referred to in Section 15 of the *Australia New Zealand Food Authority Act (1991)*.

Public comments are now sought before completion of a Final Risk Analysis Report (referred to as the “Inquiry” in Section 16 of the Act). See under ‘Invitation for Public Submissions’ for details.

## TABLE OF CONTENTS

<b>EXECUTIVE SUMMARY .....</b>	<b>3</b>
BACKGROUND .....	3
ISSUES ADDRESSED DURING ASSESSMENT .....	3
CONCLUSION .....	4
<b>INVITATION FOR PUBLIC SUBMISSIONS .....</b>	<b>5</b>
<b>INTRODUCTION.....</b>	<b>6</b>
<b>BACKGROUND TO THE APPLICATION .....</b>	<b>6</b>
<b>PUBLIC CONSULTATION .....</b>	<b>7</b>
<b>NOTIFICATION OF THE WORLD TRADE ORGANIZATION.....</b>	<b>7</b>
<b>ISSUES ADDRESSED DURING ASSESSMENT .....</b>	<b>7</b>
1. SAFETY ASSESSMENT .....	7
2. LABELLING OF FOOD PRODUCED FROM INSECT-PROTECTED CORN.....	10
3. ISSUES ARISING FROM PUBLIC SUBMISSIONS .....	10
4. RISK MANAGEMENT .....	12
<b>REGULATORY IMPACT ASSESSMENT.....</b>	<b>13</b>
<b>CONCLUSIONS .....</b>	<b>13</b>
<b>DRAFT VARIATION TO THE FOOD STANDARDS CODE.....</b>	<b>14</b>
<b>DRAFT SAFETY ASSESSMENT REPORT .....</b>	<b>15</b>
<b>DRAFT REGULATORY IMPACT ASSESSMENT.....</b>	<b>49</b>
<b>WORLD TRADE ORGANISATION AGREEMENTS .....</b>	<b>51</b>
<b>SUMMARY OF PUBLIC COMMENTS.....</b>	<b>54</b>
<b>GENERAL ISSUES RAISED IN PUBLIC COMMENTS.....</b>	<b>65</b>

## **EXECUTIVE SUMMARY**

### **Background**

ANZFA received an application from Novartis Seeds Pty. Limited on 30 April 1999 for the approval of food derived from insect-protected, herbicide-tolerant Bt-11 corn. This corn has been genetically modified to confer protection against lepidopteran pests, especially the European corn borer, and is also tolerant to the herbicide glufosinate ammonium. It is known commercially as Bt-11 corn. This report describes the scientific assessment of the application.

### **Issues addressed during assessment**

#### *(i) Safety Evaluation*

Bt-11 corn has been evaluated according to ANZFA's safety assessment guidelines. The process involves an extensive analysis of the nature of the genetic modification together with a consideration of general safety issues, toxicological issues and nutritional issues associated with the new GM food. This approach is used to establish if the food produced using GM corn and its progeny, is as safe and nutritious as food produced from conventional non-GM equivalent.

The detailed information available on the genetic modification used to produce Bt-11 corn indicates that no unintentional changes have taken place at the molecular level and that the novel genetic material is stably inserted and maintained over several generations.

Data on the potential toxicity and allergenicity of the proteins encoded by the transferred genes have been reviewed, and indicate that the new proteins expressed in food produced from Bt-11 corn are non-toxic and unlikely to have allergenic effects.

Compositional analyses demonstrate no significant differences between food produced from Bt-11 corn and its conventional counterparts. This constitutes further evidence that no unintentional effects have occurred as a result of the genetic modification.

In assessing all of the above data, ANZFA has concluded that insect-protected, herbicide-tolerant Bt-11 corn does not raise any public health and safety concerns.

#### *(ii) Labelling*

On the basis of the data considered in the safety evaluation, food derived from insect-protected, herbicide-tolerant Bt-11 corn was found to be substantially equivalent to food derived from non-GM corn. No mandatory labelling is therefore required under current labelling requirements.

It should be noted that on 28 July 2000 the Australia New Zealand Food Standards Council agreed to a revised standard which requires labelling of food where novel DNA and/or protein is present in the final food and also where the food has altered characteristics. This requirement will come into effect 12 months after the date of gazettal and may result in changes to the way in which GM foods, including those derived from Bt-11 corn, are labelled.

(iii) *Public Submissions*

Forty-five public submissions were received in relation to this application, of which only four were supportive. Those opposing the application did so primarily on the basis that they perceive GM food to be unsafe. The food safety concerns raised in submissions have been addressed by the safety assessment carried out by ANZFA, the details of which are in Attachment 2.

**Conclusion**

On the basis of available evidence, ANZFA considers that food derived from insect-protected, herbicide-tolerant corn line Bt-11 is as safe for human consumption as food from other commercial corn varieties, and is therefore proposing an amendment to the Australian *Food Standards Code* to give approval to such food. Based on the data submitted in the present application, food derived from Bt-11 corn can be regarded as substantially equivalent to non-GM corn, therefore no mandatory labelling is required, although this may change when the proposed changes to the labelling provisions of Standard A18 have been finalised.

ANZFA now seeks public comment on the proposed amendment to Standard A18 of the *Food Standards Code*, in accordance with the procedures described in Section 17 of the *Australia New Zealand Food Authority Act 1991*.

## INVITATION FOR PUBLIC SUBMISSIONS

The Authority has completed a Draft Risk Analysis Report on this application, (referred to as the 'Full Assessment' in section 15 of the Act), which includes a draft Safety Assessment report and a draft variation to the Australian *Food Standards Code*. The Authority now seeks public comment on the draft Safety Assessment Report, the draft variation to the *Food Standard Code*, and the Regulatory Impact Assessment before preparing a Final Risk Analysis Report (referred to as the 'Inquiry' in section 16 of the Act).

Written submissions containing technical or other relevant information, which will assist the Authority in preparing the Final Risk Analysis Report for this application, are invited from interested individuals and organisations. Technical information presented should be in sufficient detail to allow independent scientific assessment.

Submissions providing more general comment and opinion are also invited. The Authority's policy on the management of submissions is available from the Standards Liaison Officer upon request.

The processes of the Authority are open to public scrutiny, and any submissions received will ordinarily be placed on the public register of the Authority and made available for inspection. If you wish any information contained in a submission to remain confidential to the Authority, you should clearly identify the sensitive information and provide justification for treating it as commercial-in-confidence. The *Australia New Zealand Food Authority Act 1991* requires the Authority to treat in confidence trade secrets relating to food and any other information relating to food, the commercial value of which would be, or could reasonably be expected to be, destroyed or diminished by disclosure.

All correspondence and submissions on this matter should be addressed to the **Project Manager - Application A386** at one of the following addresses:

Australia New Zealand Food Authority

PO Box 7186  
Canberra Mail Centre ACT 2610  
AUSTRALIA  
Tel (02) 6271 2222 Fax (02) 6271 2278  
Email [info@anzfa.gov.au](mailto:info@anzfa.gov.au)

PO Box 10559  
The Terrace WELLINGTON 6036  
NEW ZEALAND  
Tel (04) 473 9942 Fax (04) 473 9855  
Email [nz.reception@anzfa.gov.au](mailto:nz.reception@anzfa.gov.au)

Submissions should be received by the Authority by **15 November 2000**.

General queries on this matter and other Authority business can be directed to the Standards Liaison Officer at the above address or by Email on [slo@anzfa.gov.au](mailto:slo@anzfa.gov.au). Submissions should not be sent by Email as the Authority cannot guarantee receipt. Requests for more general information on the Authority can be directed to the Information Officer at the above addresses.

## INTRODUCTION

The Australia New Zealand Food Authority (ANZFA) is a bi-national statutory body responsible for making recommendations on food standards which, when approved by the Australia New Zealand Food Standards Council (ANZFS), are adopted by reference and without amendment into food law. ANZFA is currently working to establish a joint Australia New Zealand Food Standards Code that will apply in both countries. In the interim, a system of dual standards operates for the majority of the food standards. Standard A18 has been accepted by New Zealand, and currently applies in both countries.

Standard A18 was adopted by ANZFS as a joint Australia/New Zealand standard in July 1998 and came into force on 13 May 1999. Under this standard, the sale of food produced using gene technology is prohibited unless the food is included in the Table to clause 2 of the standard. The standard requires that a pre-market safety assessment be conducted on all foods produced using gene technology. However, the standard provides interim arrangements for those foods currently on the market provided that an application was accepted by ANZFA on or before 30 April 1999, that the food is lawfully permitted in a country other than Australia or New Zealand, and that ANZFS has not become aware of evidence that the food poses a significant risk to public health and safety.

## BACKGROUND TO THE APPLICATION

ANZFA received an application from Novartis Seeds Pty. Limited on 30 April 1999 to amend the Australian *Food Standards Code* to include food produced from insect-protected, herbicide-tolerant Bt-11 corn in the Table to clause 2 of Standard A18 – Food Produced using Gene Technology.

The modified corn under consideration is known commercially as Bt-11 corn and is protected from attack by lepidopteran pests, particularly the European corn borer. It is also tolerant to applications of the herbicide glufosinate ammonium. The corn was developed for cultivation in the United States.

The modification involves the incorporation of two genes. The first is a truncated and modified version of the *cry1A(b)* gene from the soil bacterium *Bacillus thuringiensis* subsp. *kurstaki*. This gene codes for a protein that is toxic to Lepidoptera, and the modified corn is thus protected from attack by this type of insect pest. The second is the *pat* gene. This gene, commonly used as a selection marker, codes for the enzyme phosphinothricin acetyl transferase (PAT), and enables plants to detoxify the broad-spectrum herbicide phosphinothricin. Herbicide tolerance is thus conferred to the genetically modified corn line, enabling the crop to survive under conditions that would kill conventional corn.

Bt-11 corn is not currently grown in either New Zealand or Australia. However, domestic production of corn in both countries is supplemented by a small amount of imported corn-based products, largely as high-fructose corn syrup, which is not currently manufactured in either Australia or New Zealand. Corn-based products are processed into breakfast cereals, baking products, extruded confectionary and corn chips. Other corn products, including maize starch, are also imported. This is used by the food industry for the manufacture of dessert mixes and canned foods. In addition, sweet corn varieties are also grown for human consumption. According to the applicant, grain harvested from Bt-11 **field corn** will enter the food chain only after processing. However, Bt-11 corn has also been bred with **sweet corn** varieties, and it is

possible that these hybrid varieties may be consumed as fresh produce, as well as canned, frozen or dehydrated in powder form.

The main benefits of Bt-11 corn are agronomic in nature, and are therefore likely to accrue mainly to the primary producer. It is envisaged that target pests, in particular the European Corn Borer, should be easier to control, with lower expenditure on labour and pesticides and higher overall crop yields. More general benefits may flow to the community as a result of reduced primary production costs.

## **PUBLIC CONSULTATION**

ANZFA completed a Notice of Application (formally referred to as the Preliminary Assessment Report) upon receipt of the application and called for public comment on 3 November 1999. A total of 45 submissions were subsequently received. Attachment 5 contains a summary of the submissions.

## **NOTIFICATION OF THE WORLD TRADE ORGANIZATION**

During the ANZFA assessment process, comments are also sought internationally from other Members of the World Trade Organization (WTO). As Members of the WTO, Australia and New Zealand are signatories to the agreements on the Application of Sanitary and Phytosanitary Measures (SPS Agreement) and on Technical Barriers to Trade (TBT Agreements) (for further details on WTO, see Attachment 4). In some circumstances, Australia and New Zealand have an obligation to notify the WTO of changes to food standards to enable other member countries of the WTO to make comment.

As there is significant international interest in the safety of these foods, the proposed changes to Standard A18 are considered to raise potential Technical Barrier to Trade or Sanitary/Phytosanitary matters and will therefore be notified to the WTO.

## **ISSUES ADDRESSED DURING ASSESSMENT**

### **1. Safety assessment**

The safety assessment was performed according to the safety assessment guidelines prepared by ANZFA<sup>1</sup> and considered the following issues: (1) the nature of the genetic modification; (2) general safety issues such as novel protein expression and the potential for transfer of novel genetic material to cells in the human digestive tract; (3) toxicological issues; and (4) nutritional issues.

#### *Nature of the genetic modification*

Bt-11 corn was generated by the transfer of two new genes, a truncated *cry1A(b)* gene (referred to as the *Btk* gene) and the *pat* gene. Both genes were derived from bacteria and were modified at the DNA sequence level to increase their level of expression in the plant. The modification to the DNA sequence of each gene did not result in any changes to the amino acid sequence of the

---

<sup>1</sup> ANZFA (1999) Guidelines for the safety assessment of foods to be included in Standard A18 – Food Produced Using Gene Technology.

proteins. The corn transformation was carried out using a protoplast transformation/regeneration system.

The *cry1(A)b* gene is one of several isolated from the bacterium *B. thuringiensis*, which encode a group of toxins known as the *Bt* toxins. These toxins are selectively active against several groups of insects such as moths and butterflies, beetles, and flies and mosquitos. The *Bt* toxin produced by the *cry1(A)b* gene is known as Cry1(A)b and is selectively active against lepidopteran insects. The protein becomes active against the target insect through ingestion. In the insect gut, the protein binds to specific receptors on the insect midgut, inserts into the cell membrane and forms ion-specific pores. These events disrupt the digestive processes and cause the death of the insect.

The *pat* gene is derived from the microorganism *Streptomyces viridochromogenes* strain Tu494, and codes for the enzyme phosphinothricin acetyl transferase (PAT). This modifies and inactivates the herbicide glufosinate ammonium, and its presence thus confers tolerance to the plant. As discussed earlier, the gene was originally used only as a selection marker to distinguish genetically modified plant cells from unmodified cells. However, since the enzyme is expressed at a level high enough to confer tolerance to the plant, it has the added benefit that the herbicide can be used in the field.

In addition to the two genes transferred to the final plant, an antibiotic resistance gene, the *bla* gene was used as a selection marker when the plasmid was being generated in *E. coli*. However, the gene was removed from the plasmid prior to transformation of the final plant, and is thus not present in Bt-11 Corn.

Both the *cry1(A)b* and the *pat* gene were found to be stably integrated as single copies, and maintained in corn plants over multiple generations. They were also found to be inherited in a Mendelian manner, and always segregated together.

### *General safety issues*

Corn represents a staple food for a significant proportion of the world's population. Corn-based products are routinely used in a wide range of foods, and have a long history of safe use. Sweet corn varieties are grown largely for human consumption, although corn grain is also widely used as an animal feedstuff.

The Bt-toxin expressed in the modified corn, though in truncated form, was found to be equivalent to that occurring naturally, and equivalent to that produced for use as the biopesticide that is widely used by the organic food industry. The expression level of the protein was generally low, and varied in different plant parts. The level of expression was fairly low in the kernel, the part used for human consumption, with a maximum level of 3.17 µg/g fresh weight. Once processed (canned) the kernels were found to contain no detectable Bt-protein.

Phosphinothricin acetyl transferase (PAT) is specific for the herbicide phosphinothricin (as well as the natural substrate produced by *S. viridochromogenes*), neither of which are found in the human body. Although the level of expression of the enzyme in Bt-11 corn is sufficiently high for the corn to be regarded as herbicide-tolerant, these high levels were only found in the tassels and leaves. No enzyme was detectable in the kernels, pollen, silk, stalk or root.

Although the plasmids used in the transformation process of Bt-11 corn contain the antibiotic resistance gene *bla*, the gene was not transferred to the modified plant. The impact on human health from its potential transfer to gut micro-organisms was therefore not considered. The transfer of novel genetic material from Bt-11 corn to human cells via the digestive tract was assessed, but was considered to be extremely unlikely to occur, and unlikely to pose any special additional risks compared with the large amount of DNA naturally present in all foods.

### *Toxicological issues*

The presence of naturally-occurring toxins and allergens in Bt-11 corn was investigated, as well as the potential toxicity and allergenicity of the Cry1(A)b and PAT proteins.

Corn contains no naturally-occurring toxins or allergens, and as noted above has a long history of safe use.

Biochemical studies confirmed the equivalence of the truncated Bt-toxin to that produced naturally. The novel protein, which is equivalent to that present in *B. thuringiensis* formulations, has been used commercially for many years to control insect pests. These formulations have been used extensively with no evidence of toxicity to humans, or to non-target species of insects, birds, fish or mammals. The potential acute oral toxicity of Cry1(A)b was assessed in mice. No adverse findings were seen in the animal studies. On the basis of this evidence, it can be concluded that Cry1(A)b, as expressed in insect-protected, herbicide-tolerant corn line Bt-11, is non-toxic to humans. The toxicity of PAT protein was assessed using similar studies. Results from acute oral toxicity testing in mice did not indicate any toxic effects. In addition, the substrate for the enzyme is not found in humans and PAT shows no amino acid similarity to known toxins.

The potential for the novel proteins to be allergenic was investigated using a number of criteria, including amino acid sequence homology with known allergens, history of use and common physicochemical properties of allergens, including the sensitivity to digestion by digestive enzymes. As already discussed, Cry1(A)b has a long history of safe use, and shares no characteristics or similarity with known allergens. In laboratory tests it was found to be rapidly digested in conditions that mimic human digestion, and was found to be identical to the microbially-produced protein in terms of immunoreactivity, molecular weight, trypsin resistance, glycosylation and bioactivity. The PAT protein too was found to be rapidly digested in conditions that mimic human digestion. In addition, it is present at very low levels, if at all, in corn kernels, and shows no amino acid similarity to known allergens.

### *Nutritional issues*

Detailed compositional analyses were carried out to establish the nutritional adequacy of Bt-11 corn, and to look for any unintended effects by comparing it to non-modified control lines. The composition of maize and sweet corn lines were assessed, including fresh and canned sweet corn lines. The effect of glufosinate ammonium use on the composition of corn kernels was also examined. Samples were taken from trials in both Europe and the USA. Composition in terms of key chemical components (total protein, oil, starch and fibre), including fatty acids, amino acids, vitamins and minerals was investigated.

Results revealed few significant differences between Bt-11 corn and control samples, confirming that insect-protected, herbicide-tolerant Bt-11 corn is compositionally equivalent to other

commercial corn lines. Although small but significant differences were seen in protein content and the levels of two amino acids (cysteine and arginine) of some Bt-11 lines, these effects were not consistent between field trial sites or hybrid lines, and are likely to reflect natural variation rather than any effect of the modification. Levels of vitamins and minerals, chemical composition, and fatty acid content were all unaffected by the modification, in both canned and fresh produce. Glufosinate ammonium treated samples were also examined and there were no significant differences between genetically modified and control lines, except for the levels of the amino acids proline and alanine, which were lower in treated Bt-11 corn than in the control lines. These differences are not considered to raise safety or nutritional concerns and are considered likely to reflect normal variation in corn hybrids.

Corn does not contain natural toxins or anti-nutrients at a level that is considered biologically significant.

Animal feeding studies were not considered essential in this case because sufficient information had been provided about the genetic modification and the composition of the food. It can be concluded from the data provided that Bt-11 corn is nutritionally adequate.

### *Conclusion*

On the basis of the data submitted in the present application, insect-protected, herbicide-tolerant Bt-11 corn is equivalent to other commercially available corn in terms of its safety and nutritional adequacy.

## **2. Labelling of food produced from insect-protected corn**

Clause 3 of Standard A18 prescribes mandatory labelling of a food produced using gene technology when it contains new or altered genetic material and where it is not substantially equivalent in any characteristic or property of the food. As Bt-11 corn has been found, on the basis of data submitted with the present application, to be equivalent to other commercial varieties of corn there is no requirement for mandatory labelling under the current standard.

It should be noted that on 28 July 2000 the Australia New Zealand Food Standards Council agreed to a revised standard which requires labelling of food where novel DNA and/or protein is present in the final food and also where the food has altered characteristics. This requirement will come into effect 12 months after the date of gazettal and may result in changes to the way in which GM foods, including those derived from Bt-11 corn, are labelled.

## **3. Issues arising from public submissions**

### **3.1 General issues**

Of the 45 submissions received, only a small number addressed issues specific to this application. Rather, the majority of submissions raised issues of a general nature relating to gene technology or issues that had already been addressed in the safety assessment report (see Attachment 2). A discussion of some of the general issues in relation to gene technology that were raised in public submissions can be found in Attachment 6.

## 3.2 Specific issues

This section of the report will only address those issues raised in public submissions that are specific to an assessment of this application.

### (i) Use of *Bt* toxins – toxicity and allergenicity concerns

Mr Arnold Ward, the National Council of Women of Australia and the Health Department of Western Australia raised concerns about the effect of *Bt* toxin on humans. The Australian GeneEthics Network stated that the *Bt* insecticidal proteins have no history of safe use in the animal and human food supplies and that their long-term impacts are unknown. The New Zealand Ministry of Health (NZMH) noted the epidemiological evidence regarding the safety of *Bt* proteins used as the active ingredient of insecticidal sprays, but considered that ANZFA's assessment should address the biochemistry of the *Bt* protein, and why it is unlikely to cause any harmful effects when consumed by humans. NZMH also suggested that the dietary intake of *Bt*-toxin should be calculated.

### Response

The toxicity and allergenicity of the *Bt* toxin are reviewed in the draft safety assessment report (Attachment 2). *Bt* toxins have a long history of safe use as insecticidal sprays applied directly to crops for over 30 years with no reports of human, or mammalian, toxicity or allergenicity.

While it is correct that the Cry1A(b) protein is not used directly as a food or in a feed source, *Bacillus thuringiensis* is nevertheless ubiquitous in nature and commonly present as a contaminant on food. The donor organism *B. thuringiensis* subsp. *kurstaki* (*B.t.k.*), which produces the insecticidal protein, is the basis of microbial formulations used commercially for Lepidopteran insect control for over 30 years. These microbial formulations have been used on a wide variety of crops, including fresh produce such as lettuce and tomato, with no reports of human, or mammalian, toxic or allergenic responses.

The mode of action of the *Bt* toxins has been thoroughly studied. The *Bt* toxin (Cry) proteins only bind to specific receptors on the surface of gut cells of specific insects. Binding of the Cry protein results in lysis of insect midgut epithelial cells, leading to gut paralysis, cessation of feeding and the eventual death of the insect. These receptors do not exist in humans or mammals and it can therefore be inferred that the *Bt* toxins are highly unlikely to exert any toxic effects in mammals, including humans. The Cry1A(b) protein does not share the biochemical properties common to known allergens.

The applicant provided direct experimental evidence of the absence of acute toxicity in mice and birds, with doses of up to 5050 mg protein/kg, far higher than those estimated to be ingested through normal dietary intake. No adverse effects were observed in six week feeding study in chickens, in which *Bt*-176 corn formed the major portion (greater than 60%) of the diet. The level of the Cry1A(b) protein in corn kernels, the only part of the plant used for human food, is very low – less than 5 ng/g fresh weight or 5 parts per billion, which is at the limit of quantification. The dietary exposure will be lower than that experienced through eating products sprayed with *Bt*-based insecticides. The processing steps for corn would be expected to remove and/or destroy the Cry1A(b) protein. Thus the level of Cry1A(b) protein present in processed products derived from *Bt*-176 corn would be extremely low.

It is therefore concluded that consuming food products derived from corn containing these proteins is extremely unlikely to result in adverse effects in humans

(ii) *Toxicity of glufosinate ammonium breakdown products*

The South Australia Public and Environmental Health Service raised the point that the ANZFA safety assessment should address the issue of whether residues of the herbicide degradation process are present, toxic and/or subject to an MRL. The Consumers' Association of South Australia Inc. & National Council of Women of Australia raised similar concerns.

Response

There is currently no MRL for either glufosinate ammonium or its metabolites in corn in Australia. Similarly, in New Zealand no MRL exists, although a level of 0.1 ppm is allowed under default clause 6b of the regulation 257 (2A). A Codex MRL of 0.1 ppm also exists. There is no evidence to suggest that the metabolites MPP and MPA are any more toxic than glufosinate, and sub-chronic and developmental studies in the US concluded that they were of similar or lower toxicity compared to the parent compound.<sup>2</sup> The chemical is permitted for use on Bt-11 corn in the USA and the US regulatory assessment concluded that a single tolerance limit of 0.2 ppm was suitable for field corn. The consumption of food produced from Bt-11 corn is therefore not considered to pose a risk to human health.

#### **4. Risk management**

Under Standard A18, a GM food must undergo a safety assessment in accordance with ANZFA's safety assessment guidelines. The requirement for the food to be labelled must also be assessed in accordance with the labelling criteria specified in clause 3 of the standard.

On the basis of the conclusions from the safety assessment report, together with a consideration of the public submissions, it is proposed that Table 1 to clause 2 of Standard A18 be amended to include food from insect-protected, herbicide-tolerant Bt-11 corn. The proposed amendment is provided in Attachment 1.

In relation to labelling of the food, the safety assessment report found that, on the basis of the data provided in the application, food from insect-protected, herbicide-tolerant Bt-11 corn is substantially equivalent to that from other commercially available corn in terms of its safety and nutritional adequacy. Therefore, under the current standard, no mandatory labelling is required. However, a decision made at the Australia New Zealand Food Standards Council (ANZFSC) meeting on 28 July 2000 will result in changes to the way some GM foods, including those derived from Bt-11 corn are labelled. It is expected that the new standard will require labelling of food and ingredients where novel DNA and/or protein is present in the final food, or where the food has altered characteristics. Some types of food are expected to be exempt, e.g. certain highly refined products and processing aids. The revised standard is currently being drafted, and will come into effect 12 months after gazettal.

In relation to the concerns raised in the public submissions with regard to gene technology and GM food, ANZFA has prepared a public discussion paper on the safety assessment process for

---

<sup>2</sup> US Federal Register, Volume 65 (98), May 19 2000.

GM food<sup>3</sup>. This is widely available and may assist in addressing some of the concerns raised by the public. Other government and industry bodies are also addressing the broader concerns in relation to gene technology.

## **REGULATORY IMPACT ASSESSMENT**

The benefits and costs associated with the proposed amendment to Standard A18 have been analysed in a draft Regulatory Impact Statement (Attachment 3). The benefits of the proposed Standard A18 amendment to approve food from insect-protected, herbicide-tolerant Bt-11 corn primarily accrue to the food industry and government, with potentially a small benefit to the consumer.

## **CONCLUSIONS**

It is concluded that:

- the introduced genes in insect-protected, herbicide-tolerant Bt-11 corn are not considered to produce any increased public health and safety risk;
- on the basis of the data provided in the application, food derived from insect-protected, herbicide-tolerant Bt-11 corn is equivalent to food derived from other commercial varieties of corn in terms of its safety and nutritional adequacy;
- food derived from insect-protected, herbicide-tolerant Bt-11 corn does not require labelling under the current provisions of Standard A18 as it is substantially equivalent to food derived from non-GM corn. Recently agreed amendments to the labelling provision of Standard A18 may result in some Bt-11 corn food products being labelled in the future;
- the benefits to government, consumers and industry associated with the proposed amendment outweigh the costs.

## **ATTACHMENTS**

1. Draft variation to the Australian *Food Standards Code*
2. Draft safety assessment report
3. Draft regulatory impact assessment
4. World Trade Organization Agreements
5. Summary of public comments
6. General issues raised in public comments

---

<sup>3</sup> ANZFA (2000) GM foods and the consumer: ANZFA's safety assessment process for genetically modified foods. ANZFA Occasional Paper Series No. 1.

**DRAFT VARIATION TO THE FOOD STANDARDS CODE**

*Standard A18 is varied by inserting into Column 1 of the Table to clause 2 –*

Food derived from herbicide-tolerant Bt-11 corn.

**DRAFT SAFETY ASSESSMENT REPORT**

**A386 – FOOD DERIVED FROM  
INSECT-PROTECTED, HERBICIDE-TOLERANT CORN Bt-11**

## SUMMARY AND CONCLUSIONS

### Nature of the genetic modification

A proprietary inbred corn line, H8540, was transformed with two genes — the *pat* and *cry1(A)b* genes to generate Bt-11 corn. Bt-11 corn contains a single copy of each gene at one chromosomal location in the corn genome. No other genes were transferred.

The *cry1(A)b* gene is one of several genes from the bacteria *Bacillus thuringiensis*, which encode toxins collectively known as the *Bt* toxins. These toxins are selectively active against groups of insects such as moths and butterflies, beetles, and flies and mosquitos. The *Bt* toxin produced by the *cry1(A)b* gene is known as the Cry1(A)b protein and is selectively active against lepidopteran insects. This gene has been transferred to corn to protect it specifically against the European Corn Borer.

The *pat* gene is derived from the bacteria *Streptomyces viridochromogenes* and encodes for the enzyme phosphinothricin acetyl transferase (PAT), which enables plants to detoxify the broad-spectrum herbicide phosphinothricin (which is the active moiety of glufosinate ammonium). This protein enables the selection of genetically modified plant cells from unmodified cells and also confers herbicide tolerance to the genetically modified corn line.

The transformed corn was shown to be phenotypically and genotypically stable by segregation and mapping studies over multiple generations.

### General safety issues

Corn represents a staple food for a significant proportion of the world's population. Corn-based products are routinely used in an enormous number and diverse range of foods, and have a long history of safe use. Products derived from Bt-11 corn may include highly processed corn products such as flour, breakfast cereals, high fructose corn syrup and other starch products as well as products derived from fresh sweet corn varieties (frozen, canned and powdered products).

The transformed corn produces two new proteins: Cry1A(b) and phosphinothricin acetyltransferase (PAT). The expression of both proteins in the corn kernels is low – Cry1A(b) was expressed to a maximum level of 3.17 µg/g fresh weight of sweet corn and a maximum of 1.6 µg/g fresh weight of maize varieties and the PAT protein was below the limit of detection in all lines tested. Cry1A(b) was below the level of detection in canned sweet corn.

One of the important issues to consider in relation to genetically modified foods is the impact on human health from potential transfer of novel genetic material to cells in the human digestive tract. This concern primarily refers to the presence of antibiotic resistance genes in genetically modified foods. Bt-11 corn does not contain any antibiotic resistance genes and therefore it was not necessary to address this issue in this assessment. Transfer of the *cry1(A)b* and *pat* genes from Bt-11 corn to human cells via the digestive tract was considered to be unlikely. As the amount of novel genetic material in Bt-11 corn is minute compared to the total amount of DNA present, it is unlikely to pose any additional risks compared with the large amount of DNA naturally present in all foods.

## **Toxicological issues**

Corn does not have any naturally-occurring toxins or allergens and has a long history of safe use.

The Cry1(A)b and PAT proteins are present at low levels in kernels of Bt-11 corn lines tested. The potential toxicity and allergenicity of the Cry1(A)b and PAT proteins were investigated.

In acute toxicity studies of the Cry1A(b) and PAT proteins in mice, there were no signs of toxicity at a dose of approximately 3.5 g/kg and 2.6 g/kg bodyweight respectively. The newly expressed proteins were readily degradable in simulated gastric conditions and neither protein has similarity with known toxins or allergens. The Cry1A(b) protein is present in low levels in kernels of both maize and sweet corn varieties, and could not be detected after processing (canning) of sweet corn. The PAT protein was below the level of detection in kernels of all varieties tested. These results suggest that dietary exposure to Cry1A(b) and PAT from consumption of Bt-11 corn kernels would be very low.

## **Nutritional issues**

Detailed compositional analyses were assessed to establish the nutritional adequacy of Bt-11 corn and to compare it to non-modified control lines of a similar genetic background. No consistent differences in major components or nutrients were observed in Bt-11 corn varieties compared to their respective control lines, or in plants treated with herbicide compared to untreated controls.

Although some statistically significant differences were observed, these were small and random and are not considered to have any biological significance or raise any safety or nutritional concerns. All values reported in the study are consistent with ranges cited in the published literature. The results support the conclusion that Bt-11 corn is nutritionally and compositionally comparable to non-modified corn hybrids and that no health risks are associated with consumption of food derived from the genetically modified corn.

## **Conclusion**

No potential public health and safety concerns have been identified in the assessment of insect protected, herbicide tolerant Bt-11 corn. On the basis of the data considered in the present application, genetically modified Bt-11 corn is equivalent to other commercially available corn in terms of its safety and nutritional adequacy.

## 1. BACKGROUND

Novartis Seeds Pty. Ltd. have made an application to ANZFA to amend Standard A18 of the Australian *Food Standard Code*, to include food derived from corn that has been genetically modified for protection against insects, specifically the European corn borer (ECB) and tolerant to the herbicide glufosinate ammonium. The corn is referred to as 'Bt-11 corn'.

Protection against the European corn borer is achieved through the expression in the plant of a modified, truncated version of the *cry1A(b)* gene which produces a nature identical insecticidal protein, CryIA(b). Cry1A(b) is produced naturally by the spore-forming soil bacterium *Bacillus thuringiensis kurstaki* strain HD-1 (*B.t.k.*).

Tolerance to the herbicide glufosinate ammonium is achieved through the expression of the *pat* gene, which produces the enzyme, phosphinothricin acetyl transferase (PAT) that chemically modifies the herbicide, thus rendering it inactive.

Bt-11 corn has been crossed into both maize and sweet corn varieties. Maize varieties are generally classified into flint, pop, dent and flour lines based on the hardness of the kernel. Flint varieties are preferred by dry millers for flour, grits and meal based products such as cereals and dent varieties are preferred by wet millers for starch and starch based products such as high fructose corn syrup. Corn oil may be produced from the germ of all varieties. Fermentation of cereal grains is also used for beverage and alcohol production.

A wide variety of food products are derived from the genetically modified corn including highly processed corn-based food ingredients such as high-fructose corn syrup, which is not currently manufactured in either Australia or New Zealand. Maize starch is also used by the food industry for the manufacture of dessert mixes and canned foods. Corn-based ingredients can also be processed into breakfast cereals, baking products, extruded confectionary and corn chips.

As well as these highly processed foods, foods produced from sweet corn varieties may be consumed as fresh, canned or frozen corn or dehydrated in powder form.

## 2 DESCRIPTION OF THE GENETIC MODIFICATION

### 2.1 Methods used in the genetic modification


A proprietary inbred corn line, H8540, was transformed with the vector pZ01502 to transfer two new genes, a truncated *cry1(A)b* gene (referred to as the *cry1A(b)* gene) and the *pat* gene. The line was transformed using a protoplast transformation/ regeneration system similar to that described by Negrutiu *et al* (1987). The vector is derived from the plasmid pUC18 and contains the following additional sequences:

- the *bla* (or *amp*) gene under the control of a bacterial promoter, encoding a  $\beta$ -lactamase, which confers resistance to ampicillin;
- a nonfunctional *lac Z* gene, encoding a portion of a  $\beta$ -galactosidase; and
- the pUC origin of replication derived from the plasmid pBR322.

This plasmid does not contain the *tra* (transfer) and *nic/bom* (nick/basis of mobility) genes required for conjugation. The *bla* gene was used as a selection marker when the plasmid was being generated in *Escherichia coli*, but was removed before transformation of plant cells. Thus,

the transformation of corn resulted in the transfer of only one *cry1A(b)* gene and one *pat* gene. The insect-protected, herbicide-tolerant corn varieties designated ‘Bt-11 corn’, are the subject of this application and were derived from the original transformant.

**Figure 1: Schematic diagram of pZ01502<sup>1</sup>**



<sup>1</sup>See text or Table 1 for an explanation of the abbreviations.

<sup>2</sup>The transferred DNA is denoted by the arrows. The two boxed regions denote the novel genes introduced into Bt-11 corn.

<sup>3</sup>The genes in the entire plasmid including the antibiotic resistance gene, *bla*.

## 2.2 Function and regulation of the novel genes

The genes transferred to the corn genome and their regulatory sequences are outlined in Table 1.

**Table 1: Description of Genes transferred to Corn**

Genetic Element	Origin	Role
<i>cry1A(b)</i> 35S Promoter	Bt gene from <i>Bacillus thuringiensis</i> cauliflower mosaic virus 35S gene	A crystal protein toxic to Lepidopterans Promoter of high level constitutive gene expression in plant tissues
IVS9 Enhancer  NOS 3' Untranslated region	intron from corn alcohol dehydrogenase 1S gene  <i>A. tumefaciens</i> nopaline synthase gene	A regulatory sequence that enhances gene expression in the plant  Contains the signal for the termination of transcription and directs polyadenylation
<i>Pat</i> 35S Promoter	Phosphinothricin acetyl transferase from <i>Streptomyces viridochromogenes</i> modified figwort mosaic virus 35S promoter	Confers tolerance to glufosinate ammonium  Promoter of high level constitutive gene expression in plant tissues
IVS2Enhancer  NOS 3' Untranslated region	intron from corn alcohol dehydrogenase 1S gene  <i>Agrobacterium tumefaciens</i> nopaline synthase gene	A regulatory sequence that enhances gene expression in the plant  Contains the signal for the termination of transcription and directs polyadenylation

### *The cry1A(b) gene*

The *cry1A(b)* gene derived from the soil bacterium *Bacillus thuringiensis* subspecies *kurstaki* (*Btk*) strain HD1 confers protection against attack from certain species of lepidoptera, including the European corn borer (ECB) (Geiser *et al*, 1986). The DNA sequence of the gene has been truncated at the 3' end and modified to increase the level of expression in corn, but the amino acid sequence of the protein has not been altered (Perlak *et al*, 1991). The *cry1A(b)* gene in Bt-11 corn codes for the Cry1A(b) protein, a truncated version of the  $\delta$ -endotoxin produced by *B. thuringiensis*.

Plasmid pZ01502 contains one copy of the *cry1A(b)* gene, controlled by the untranslated 35S promoter from cauliflower mosaic virus (CaMV) and the NOS 3' untranslated region from the nopaline synthetase gene of *Agrobacterium tumefaciens* (NOS 3'). The *cry1A(b)* gene is fused to an intron from the corn alcohol dehydrogenase 1S gene (IVS9) to enhance gene expression in the plant (Mascarenhas *et al*, 1990).

### ***The pat gene***

The *pat* gene is derived from the soil microorganism *Streptomyces viridochromogenes* strain Tu494. It codes for the enzyme phosphinothricin acetyl transferase (PAT) which modifies and inactivates the herbicide glufosinate ammonium (Strauch *et al*, 1988).

Plasmid pZ01502 contains one copy of the *pat* gene, which uses the same promoter and 3' untranslated sequence to direct initiation and termination of transcription of the mRNA as the *cry1(A)b* gene (the CaMV 35S promoter and NOS 3' termination signal). The *pat* gene is also fused to an intron from the corn alcohol dehydrogenase 1S gene (IVS2) to enhance gene expression in the plant (Mascarenhas *et al*, 1990). The native DNA sequence of the gene has been altered to optimise expression in plants (Wohlleben *et al*, 1988) but the amino acid sequence of the PAT protein is unaltered. The changes to the DNA sequence alter codon usage to lower the GC content.

### ***The bla gene***

A *bla* gene was used as a selectable marker to distinguish transformed bacterial cells from non-transformed cells. It codes for a  $\beta$ -lactamase enzyme that confers resistance to some  $\beta$ -lactam antibiotics, including the moderate-spectrum penicillin and ampicillin. Bacterial cells that contained the pZ01502 plasmid were selected through their resistance to ampicillin. The *bla* gene was excised from the gene construct before transformation of corn embryos and is therefore not present in Bt-11 corn. This has been demonstrated by Southern blot and specific-primer PCR analyses.

## **2.3 Characterisation of the genes in the plant**

Novartis submitted the following study regarding characterisation of the novel genes in Bt-11 and stability of genetic changes.

Hilleshög NK (1996). Molecular characterisation of the genetically modified (Bt-11) maize.

Southern blot experiments confirmed the presence of the *cry1(a)b* and *pat* genes in bt-11 corn lines and the absence of the *bla* gene. Prior to transformation, the plasmid DNA was digested with restriction enzymes to produce the DNA fragment containing only the *cry1(a)b* and *pat* genes. The *bla* gene was specifically removed by this digest therefore producing a DNA fragment without any antibiotic resistance genes (illustrated in figure 1).

Southern blot and polymerase chain reaction (PCR) analyses of the Bt-11 corn line was used to support the absence of the *bla* gene. No positive signal was obtained when using a *bla* probe in Southern blots. PCR analysis of the genetically modified corn line, Bt-11, also indicated that it did not contain the *bla* gene. Both Southern blotting and PCR are sensitive enough to detect a single copy of the *bla* gene.

The PCR-walking technique was used to determine that a 1.4 Kb DNA fragment of the vector sequence, upstream from the *cry1A(b)* gene including the origin of replication is transferred to the Bt-11 corn genome. The DNA fragment transferred to Bt-11 corn includes the two novel genes and the bacterial origin of replication (*ori*) from the pUC18 plasmid.

#### **2.4 Stability of the genetic changes**

The stability of the inserted DNA in Bt-11 corn was demonstrated by a Mendelian inheritance pattern. The segregation of the *cry1A(b)* and *pat* genes and their phenotypic traits was followed over multiple generations. F1 plants (first generation hybrids) were identified as containing the *cry1A(b)* and *pat* genes. These plants were self-fertilised to produce the S1 population. This S1 population was screened for protection against the European corn borer and for tolerance to glufosinate ammonium. The S1 plants were again self-fertilised. The insect protection and herbicide tolerance traits were then backcrossed into two genetic backgrounds (H8540 and 977), and in some cases, followed by further self-fertilisation.

Seed was collected from corn plants exhibiting both new traits representing different backcross stages and planted in the field for analysis in 1994 and 1995. Plants were tested for protection against the European corn borer and tolerance to glufosinate ammonium. All plants were either both tolerant to the herbicide and protected against insect attack or susceptible to both with segregation patterns consistent with the expected ratio for a single dominant locus, for that particular generation.

The stability of the insert and specifically the *pat* and *cry1(A)b* genes was also demonstrated from R<sub>3</sub> and R<sub>6</sub> generations using Southern blot analysis. Segregation analyses for Bt 11 corn for the six generations of backcrosses and also for crosses with two inbred corn lines are consistent with a stable, single dominant gene segregating according to Mendelian genetics.

Plants screened for protection against insect attack (bioassays with the European corn borer) and for tolerance to the herbicide glufosinate ammonium demonstrated these phenotypes and inheritance patterns consistently over multiple generations. These studies also demonstrated that the *cry1(A)b* and *pat* genes are closely linked, as they always segregated together.

Restriction fragment length polymorphism (RFLP) mapping was used to determine the location of the novel genes in Bt-11. The progeny of Bt-11 plants crossed with the two inbred corn lines were screened with RFLP probes, corresponding to different regions of the corn genome. Comparison of the genotypes of the progeny with isogenic controls demonstrated that the site of integration for the genetic material in Bt-11 corn is located on the long arm of chromosome 8.

#### **2.5 Conclusion regarding the nature of the genetic modification**

A single copy of the *cry1A(b)* and *pat* genes are transferred to corn resulting in the development of an insect protected (lepidopteran), herbicide tolerant (glufosinate ammonium) Bt-11 corn. Segregation analyses indicate that the transferred DNA is integrated into the corn genome as a single and stable insert. Further molecular studies indicated that the insertion site is on the long arm of maize chromosome 8.

### **3. GENERAL SAFETY ISSUES**

The Bt-11 corn has been assessed according to the safety assessment guidelines developed by ANZFA, relating to Group D foods - food ingredients, ie plants or animals that contain new or altered genetic material (ANZFA 1999).

### **3.1 History of use**

Corn has been cultivated for centuries and is used as a basic food item by people throughout the world (Wright, 1987). Most corn production is used for human consumption, and a wide variety of food products are derived from corn kernels. Sweet corn varieties are grown largely for human consumption. Corn grain is also widely used as an animal feedstuff.

Two milling procedures are used in corn processing – dry and wet milling. Dry milling is a mechanical process in which the endosperm is separated from the other components of the kernels and fractionated into coarse particles (grits). The process is used to produce meal and flour for use in cereals, snack foods and bakery products, or for use in brewing (Alexander, 1987). Food products derived from dry milling include flakes and grits. Corn flakes are produced by a process that involves high temperature and pressure and grits are prepared by boiling.

The wet milling process is designed to physically separate the major component parts of the kernel: starch, protein, oil and fibre. Wet milling produces primarily starch (typically 99.5% pure). In this process grain is steeped in slightly acidic water for 24–48 hours before being milled. Starch is separated from other solids through a number of grinding, washing and sieving steps. Washed starch may contain 0.3-0.35% total protein and 0.01% soluble protein. These treatments would be expected to degrade and remove proteins (May, 1987). Oil is produced from wet-milled corn by solvent extraction and heat (ie 120°C) and corn oil is considered free of protein (Rogers, 1990).

Bt-11 has been crossed with elite maize and sweet corn hybrid varieties. Grain harvested from Bt-11 maize corn (ie. predominantly dent corn varieties) will be consumed only after processing as either starch based products like high fructose corn syrup or dry milling corn-based products such as breakfast cereals and flour. Bt-11 sweet corn may also be consumed fresh, canned, frozen or dehydrated in powder.

A summary of the Bt-11 lines analysed is given in Table 2. These have been divided into the elite dent and sweet corn hybrid lines. Additionally, compositional data for genetically modified plants that have been treated with herbicide during growing have been analysed.

**Table 2. Summary of lines evaluated in the application<sup>1</sup>.**

Lines	Protein Expression	Proximate <sup>2</sup>	Fatty Acids	Amino Acids <sup>3</sup>	Vitamins & Minerals
<b>Initial transformant (greenhouse data)</b>					
<b>H8540 Bt<sup>+</sup>/Bt<sup>+</sup></b>		+	+	+	
<i>Control H8540</i>		+	+	+	
<b>H8540 Bt<sup>+</sup>/Bt<sup>-</sup> hybrid</b>		+	+	+	
<i>Control hybrid</i>		+	+	+	
<b>Dent Corn</b>					
<b>N4640-CBR</b>					+
<b>X4734-CBR</b>	+	+	+	+	
<b>X4334-CBR</b>	+	+			
<b>N4242-CBR</b>					+
<i>N4640</i>		+	+	+	+
<i>NK4242</i>	+	+			+
<b>X6534-CBR</b>	+	+	+	+	
<i>X6514</i>		+			
<i>N6800</i>			+	+	
<b>X7634-CBR</b>	+	+			
<i>X7514</i>	+	+			
<b>Sweet Corn Varieties</b>					
<b>0943</b>	+	+			+
<i>Jubilee</i>	+	+			+
<b>0937</b>	+	+			+
<i>Bonus</i>	+	+			+
<b>0941</b>	+	+			+
<i>Empire</i>	+	+			+
<b>Herbicide treated plants</b>					
<b>Madera-Bt</b>		+			+
<i>Madera</i>		+			+
<b>Manuel-Bt</b>		+			+
<i>Manuel</i>		+			+
<b>Magister-Bt</b>		+			+
<i>Magister</i>		+			+

<sup>1</sup>A “+” indicates the data that was provided for that line. Control lines are in italics and genetically modified corn lines are in bold and are denoted as CBR – corn borer resistant or Bt. Control lines are either corresponding isogenic non-GM lines or are of a similar genetic background.

<sup>2</sup>Proximate components analysed were: *Initial transformants*: Total nitrogen, moisture, ash, starch, cellulose, xanthophyll; *Dent corn*: protein, oil, starch and fibre; *Sweetcorn*: moisture, protein, fat, ash, carbohydrates (total), calories, calories from fat, sugars, other carbohydrates, total dietary fibre; *Treated*: energy, carbohydrate, protein, fat, fibre.

<sup>3</sup>Some analyses did not assess all amino acids.

Corn-based food products are derived from many different corn varieties, particularly dent corn lines and sweet corn lines. The applicant has provided data on the original transformant (H8540 and hybrids), and has extended their analysis to those Bt-11 corn lines that are widely used in food production. This includes several dent corn and sweet corn lines that have been developed from conventional breeding with the original transformed line. This information on additional lines enables a comprehensive analysis of the potential impact of the novel genes in different corn genotypes.

### 3.2 Nature of novel proteins

Two new proteins are expressed in Bt-11 corn: a truncated form of the insecticidal protein CryIA(b), and phosphinothricin acetyl transferase (PAT). The protein products of the novel genes in the transgenic corn have been characterised and the extent of expression determined.

#### *CryIA(b)*

The *cry1(A)b* gene transferred to Bt-11 corn codes for the CryIA(b) protein, which is an identical but truncated version of the  $\delta$ -endotoxin produced by *B. thuringiensis*. In the gut of a susceptible insect, the  $\delta$ -endotoxin is broken down to yield a smaller protein that binds to specific receptors and lyses cells in the gut, preventing feeding and thus causing death.

During sporulation, *B. thuringiensis* produces cytoplasmic inclusions containing one or more of the insecticidal crystal proteins. Most crystal proteins are synthesised intracellularly as inactive protoxins that spontaneously form small crystals, approximately 1  $\mu\text{m}$  in size. Upon ingestion by susceptible insects, the highly alkaline pH of the midgut promotes solubilisation of the protoxin-containing crystals. The protoxin is then activated by trypsin-like gut proteases which cleave off domains from the carboxy- and amino- termini, leaving a protease resistant core which is the active toxin. The active toxin binds to a highly specific glycoprotein receptor on the surface of midgut epithelial cells in the insect. Aggregation of the core toxins results in the formation of a pore through the cell membrane. These cells eventually swell and burst causing loss of gut integrity and resulting in larval death within 1 to 2 days (Hofte and Whitely, 1989; Schnepf et al, 1998)

The CryIA(b) protein produced by *B. thuringiensis* subsp. *kurstaki* is a 130 kDa protoxin, which is cleaved in the gut of a susceptible insect to give an insecticidally active 65 kDa fragment. This fragment can be generated *in vitro* by digestion of the protoxin with trypsin. The modified truncated *cry1A(b)* gene product in Bt-11 corn is a protein of 615 amino acids identical to the first 615 amino acids of the native protein, with a molecular weight of approximately 65 kDa.

#### *PAT*

*S. viridochromogenes* produces the tripeptide antibiotic, bialaphos, which consists of phosphinothricin, an analogue of L-glutamic acid bearing two alanine residues. Peptidases hydrolyse bialaphos releasing free phosphinothricin. The *pat* gene encodes phosphinothricin acetyl transferase (PAT) which breaks down bialaphos thus allowing the microorganism to protect itself against the toxic compound it produces. When transferred to plants, the *pat* gene product enables the plant to detoxify the broad-spectrum herbicide phosphinothricin (the active moiety of glufosinate ammonium herbicides).

In plants, the enzyme glutamine synthetase, plays a central role in the uptake of nitrogen by catalysing the incorporation of ammonia into glutamine. The herbicide glufosinate ammonium inhibits this enzyme in plants, leading to an accumulation of ammonia in the tissues, which kills the plant. The PAT protein catalyses the acetylation of phosphinothricin, eliminating its herbicidal activity. Acetylation of phosphinothricin produces N-acetyl-glufosinate (NAG) and two further metabolites, 3-methylphosphinopropionic acid (MPP) and 3-methylphosphinicoacetic acid (MPA).

Although Bt-11 corn is marketed only as an insect-protected plant, the presence and expression of the *pat* gene enables tolerance to commercial applications of the herbicide glufosinate ammonium and is therefore also regarded as a herbicide tolerant plant. The expression level of the PAT protein is discussed in detail in section 3.3. Bialophos, an antibiotic produced by *S. viridochromogenes* is the natural substrate for PAT. No additional substrates, apart from phosphinothricin, have been reported.

### 3.3 Expression of novel protein in the plant

Novartis submitted two studies related to this area:

Schramm S. and Warnick D. (1998). Quantification of Cry1A(b)protein in Attribute insect-protected sweet corn tissues, whole plants and processed products. Performing laboratory: Novartis Seeds Inc, Gilroy, CA, USA. Determination of phosphinothricin N-acetyl-transferase levels in Bt11 maize. Performing laboratory: Xenos Laboratories Inc.

The expression of the PAT and Cry1A(b) proteins in Bt-11 plants has been determined for several maize lines grown both in field trials and in greenhouses and also for three sweet corn lines (refer to Table 2). Expression levels of the introduced proteins were measured using enzyme linked immuno-sorbent assay (ELISA), which is a highly sensitive technique that can detect the presence of a protein generally to a sensitivity of 10 - 100 pg.

In a greenhouse experiment, various plant tissues at several stages of development were analysed for the novel proteins. A second experiment determined the expression levels for four Bt-11 maize hybrids grown in two locations (ie 2 hybrid lines per location) and a third study determined the level of the novel proteins in three sweet corn hybrids. ELISA analysis was used in the analysis of leaf tissue, kernel and canned kernels from the Bt-11 corn.

ELISA analysis of the Cry1A(b) protein levels in Bt-11 corn plants grown in the greenhouse determined that the highest levels were found in the leaf tissue (Table 3) with the highest level at day 25 on the fifth leaf (data not shown).

**Table 3: Specific concentration of the Cry1A(b) protein in Bt-11 dent corn tissues during the life cycle of plants grown in the greenhouse<sup>1</sup>.**

Tissue	ng Cry1A(b)/mg plant protein – days post planting (± SE)				
	10	25	59	84	119
<b>Roots</b>	11.7 ± 1.7	-	12 ± 3.4	18.2 ± 4	2.2 ± 1.2
<b>2nd Leaf</b>	106 ± 4.7	125 ± 5	-	-	-
<b>15th Leaf</b>	-	-	37.9 ± 2.2	10.2 ± 1.1	-
<b>Pollen</b>	-	-	1.25 ± 0.8	-	-
<b>Kernel</b>	-	-	-	8.2 ± 2.5	0.4 ± 0.4

<sup>1</sup>Values are means of samples from 5 replicate plants (n=5). Data points that are not available at a certain developmental stage are denoted as ‘-’.

The Cry1A(b) protein was detected in all plant tissue samples. A summary of the results from the greenhouse tissues is given in Table 3. Generally higher levels were detected at the younger stages of tissue development. The level of Cry1A(b) protein decreased as the plant reached full maturity and the tissues became senescent.

A second analysis was done on leaf, husk, stalk and kernels for four Bt-11 corn hybrids grown in field trials and respective control corn lines that have similar background genetics. All tissues were physiologically mature, green and healthy when sampled: leaf - distal half of the ear and next leaf up; stalk: 20 cm section from the stalk above ear; husk: the upper third of the outer husk leaf. The kernels from one location were picked at the early dent stage and at the late dent stage at the second location. The Cry1A(b) protein is expressed at very low levels in these tissues (Table 4). This is equivalent to less than 0.02% of the total protein in the seed. The highest level of the Cry1A(b) protein was found in leaf tissue, with the other plant tissues having significantly lower levels of the protein. The four hybrids produced similar levels of the Cry1A(b) protein.

The PAT protein was analysed in two Bt-11 hybrid corn lines. The protein level is below the limit of detection (ie 1ng/ml extract) in the kernel, husk and stalk and is expressed in trace amounts in the leaf (Table 4). The level of the PAT protein in the leaf represents less than 0.0005% of the total protein.

**Table 4: Mean levels of the Cry1A(b) and PAT proteins in corn tissues<sup>1</sup>.**

		Mean levels in leaf and kernel ( $\mu\text{g/g}$ fresh weight)			
		leaf	kernel	husk	stalk
X4334-CBR	Cry1A(b)	$4.3 \pm 0.66$	$1.5 \pm 0.21$	$1.1 \pm 0.26$	$0.71 \pm 0.11$
	PAT	$0.0386 \pm 0.0029$	lod <sup>2</sup>	lod	lod
X4734-CBR	Cry1A(b)	$5.05 \pm 0.35$	$1.30 \pm 0.28$	$0.84 \pm 0.18$	$0.55 \pm 0.06$
	PAT	$0.0494 \pm 0.005$	lod	nd	nd
<i>Control NK4242</i>	PAT	lod	lod	lod	lod
X6534-CBR	Cry1A(b)	$5.30 \pm 0.90$	$1.50 \pm 0.04$	$0.79 \pm 0.03$	$0.64 \pm 0.04$
X7634-CBR	Cry1A(b)	$5.24 \pm 0.78$	$1.60 \pm 0.13$	$1.04 \pm 0.23$	$0.53 \pm 0.06$
<i>Control NK7514</i>	Cry1A(b)	0	0	0	0

<sup>1</sup>n=4 for all Cry1A(b) means and n=3 for all PAT means.

<sup>2</sup>lod (limit of detection) for the procedure is 1ng PAT/ml extract. These values are considered not above background. nd: no data

A third analysis determined the level of the Cry1A(b) protein in tissues from three Bt-11 sweet corn hybrid varieties and control lines with a similar genetic backgrounds (Jubilee, Bonus and Empire). The Cry1A(b) protein levels in kernels tested at prime harvest stage were also assessed in these sweet corn hybrids that had been canned.

The level of the Cry1A(b) protein was present at low levels (Table 5) in Bt-11 sweet corn hybrids. Cry1A(b) protein was not detectable in any of the canned corn samples tested.

Given the low levels of the Cry1A(b) protein determined in kernels for all Bt-11 corn varieties (field and sweet corn) and that it was not detected in canned corn, dietary exposure to the novel protein is expected to be very low.

**Table 5: Cry1A(b) protein levels in tissues from Bt-11 sweet corn hybrids<sup>1</sup>.**

	Cry1A(b) levels in Bt-11 tissues (µg/g fresh weight)					
	Leaves		Kernel		Canned <sup>3</sup>	
	mean	range	mean	range	mean	range
Control <sup>2</sup>	0	-	0	-	nd	-
Hybrid 0943	4.53	3.87-5.18	3.17	2.54-3.80	nd	-
Hybrid 0937	3.10	2.60-3.86	1.59	1.41-1.80	nd	-
Hybrid 0941	3.31	2.66-3.92	0.78	0.51-1.08	nd	-

<sup>1</sup>Values are µg/g fresh weight. n=3 for all means except in leaves and kernels from 0943 where n=2.

<sup>2</sup>Control plants varieties are Jubilee, Bonus and Empire. Control plants had ELISA values corresponding to 0ng Cry1A(b)/g fw.

<sup>3</sup>The absorbance generated for canned samples did not exceed background (nd = not detectable). The lower limit of quantification was 2ng/g fw

### 3.4 Impact on human health from potential transfer of novel genetic material to cells in the human digestive tract

The human health considerations in this regard depend on the nature of the novel genes and must be assessed on a case-by case basis.

In 1991, the World Health Organization (WHO) issued a report of a Joint FAO<sup>4</sup>/WHO Consultation which looked at strategies for assessing the safety of foods produced by biotechnology (WHO 1991). That consultation concluded that as DNA from all living organisms is structurally similar, the presence of transferred DNA in food products, in itself, poses no health risk to consumers.

The major concern in relation to the transfer of novel genetic material to cells in the human digestive tract is with antibiotic resistance genes. Antibiotic resistance genes can be present in some transgenic plants as a result of their use as marker genes to select transformed cells. It is generally accepted that there are no safety concerns with regard to the presence in the food of antibiotic resistance gene DNA *per se* (WHO 1993). There have been concerns expressed, however, that there could be horizontal gene transfer of antibiotic resistance genes from ingested food to microorganisms present in the human digestive tract and that this could compromise the therapeutic use of antibiotics.

No antibiotic resistance genes were transferred to Bt-11 corn as indicated by Southern blot and PCR analysis.

In relation to transfer of novel genetic material from genetically modified food to human cells via the digestive tract, this is also equally unlikely to occur. In considering the potential impact on human health, it is important to note that humans have always consumed large amounts of DNA as a normal component of food and there is no evidence that this consumption has had any adverse effect on human health. Furthermore, current scientific knowledge has not revealed any DNA sequences from ingested foods that have been incorporated into human DNA. Novel DNA sequences in genetically modified foods comprise only a minute fraction of the total DNA in the food (generally less than 0.01%) and are therefore unlikely to pose any additional risks compared with the large amount of DNA naturally present in all foods.

<sup>4</sup> Food and Agriculture Organization.

### **3.5 Conclusions regarding general safety issues**

The *cry1A(b)* and *pat* genes are expressed at low levels in Bt-11 corn. Both proteins are expressed highest in the leaf tissue. The expression level of the Cry1A(b) protein is much lower in the kernel representing less than 0.02% total protein in the seed and the PAT protein is below the limit of detection in the kernel. The level of DNA and protein in highly processed corn based products is expected to be very low and in some cases, negligible. It is also likely that the proteins will be degraded and/or removed during processing steps.

No antibiotic resistance genes were transferred to Bt-11 corn during the transformation process. The novel genetic material in Bt-11 corn comprises only a minute fraction of the total DNA present in the corn and is therefore unlikely to pose any additional risks.

## **4. TOXICOLOGICAL ISSUES**

### **4.1 Levels of naturally-occurring toxins**

Corn contains no naturally-occurring toxins that occur at biologically significant levels (Wright, 1987).

### **4.2 Potential toxicity of the novel proteins**

The potential for toxicity of the newly expressed proteins, Cry1A(b) and PAT, were evaluated based on:

- . the amino acid sequence similarity with known toxins
- . acute toxicity testing in mice.
- . the resistance to digestion by proteases and acids in the model digestive/gastric system
- . their presence as a major protein component in a specified food.

The potential for acute toxicity of the Cry1A(b) and PAT proteins was assessed by evaluating physical and chemical characteristics of the proteins and also by acute oral toxicity in mice. The scientific basis for using an acute test is that known protein toxins generally act via acute mechanisms (Jones and Maryanski 1991). Another study was submitted that demonstrated equivalence of the corn-expressed Cry1A(b) protein to the microbially produced Cry1A(b) protein in terms of molecular weight, immunological reactivity, trypsin resistance, amino acid sequence, glycosylation and bioactivity.

Reports submitted by Novartis:

Kuhn JO (1994a). Cry1A(b) B.t.k. delta-endotoxin. Acute oral toxicity study in mice. Performing Laboratory: Stillmeadow Inc, Sugar Land, Texas. Sponsor: Ciba-Geigy Corporation, Research Triangle Park, NC, USA.

Kuhn JO (1995). Phosphinothricin acetyltransferase (Sample PAT-0195) Acute oral toxicity study in mice. Performing Laboratory: Stillmeadow Inc, Sugar Land, Texas. Sponsor: Ciba-Geigy Corporation, Research Triangle Park, NC

Meeusen R. and Mettler I. (1994), revised by Goy P.A. (1998). Equivalence of plant and microbially produced *Bacillus thuringiensis* subsp. *kurstaki* HD-1 protein. Performing laboratories: Novartis Seeds/Northrup King Co, University of Wisconsin, Kendrick Laboratories and Washington University School of Medicine, USA.

### 4.2.1 *CryIA(b)*

#### (i) *History of consumption*

*CryIA(b)* has a long history of safe use as an insecticide and has been repeatedly shown to be non-toxic to humans and other vertebrates. There is no evidence from the history of long use that there is any associated toxicity to humans. The toxicity of this protein is very specific to Lepidopteran insects. The lack of activity against non-target species appears to be due to a number of factors including physical differences in the gut environment and an absence of *CryIA(b)*-specific gut receptors in other organisms (Frick, 1995). Additionally, there is evidence that demonstrates that the mammalian gut contains receptors that are not comparable to those found in the gut of susceptible insects. *In vivo* studies with rats given *CryIA(b)* orally, and *in vitro* binding studies with gut tissue isolated from rats, mice, rhesus monkeys and humans did not reveal receptors for the protein (Noteborn *et al* 1995).

#### (ii) *Similarity with known toxins*

An amino acid sequence comparison of the *CryIA(b)* protein to a database of 2632 sequences detected significant similarities only to other *B. thuringiensis* insecticidal crystal proteins. The sequences were obtained from the GenBank, EMBL, Swissprot and PIR databases.

#### (iii) *Equivalence of the plant CryIA(b) protein to the bacterially produced protein.*

The test protein used in acute toxicity tests and characterisation studies was produced in *E. coli* because the genetically modified corn plants did not express enough protein for purification of large quantities. Data was presented to indicate that the bacterially produced *CryIA(b)* protein is equivalent to the plant produced *CryIA(b)* protein in terms of its molecular mass, N-terminal amino acid sequence, lack of glycosylation, and biological activity. The *E. coli* produced *CryIA(b)* is considered a suitable substitute for plant produced *CryIA(b)* in toxicity testing.

In this study, the trypsin resistant fragment of *CryIA(b)* expressed by Bt-11 corn was purified by extraction of leaf tissue, trypsin digestion and immunoaffinity purification. Analysis by SDS-polyacrylamide gel electrophoresis and Western blotting demonstrated that two related proteins are present in Bt-11 corn; one of 69 kDa (the full 615 residues coded for by the *cry1(A)b* gene) and one of 65 kDa (the expected size if the first 28 amino acids have been removed by proteolysis). Both proteins are reactive with antibodies to microbially-produced *CryIA(b)*. Trypsin treatment resulted in a single band of 65 kDa, which is equivalent to the trypsin resistant fragment of the native protein. Some lower molecular weight immunoreactive material (42 and 15 kDa) was also present, probably representing partially digested *CryIA(b)* protein. Similar results were obtained with the microbially-produced *CryIA(b)* protein.

N-terminal amino acid sequencing confirmed that the Bt-11 65 kDa protein had the expected sequence of a fragment extending from residue 29 of the native protein, consistent with the fragment having been cleaved at the trypsin sensitive site at residue 28. There was no evidence of glycosylation of either the Bt-11 or the microbially-produced *CryIA(b)*. The plant and microbially-produced *CryIA(b)* had similar bioactivity against ECB, with LD<sub>50</sub>s (µg/mL) of 0.47 and 0.50 respectively.

(iv) *Acute oral toxicity in mice – native CryIA(b)*

Hsd:S-D ICR albino mice (source: Harlan Sprague Dawley Inc, Texas) were acclimatised for at least 5 days before dosing (5/sex). They were housed individually in controlled conditions with free access to food and water, except for the 16 hours before dosing when food was withheld.

*Bacillus thuringiensis* Cry1A(b)  $\delta$ -endotoxin (lot BFL0194, purity 70%, source SIGMA Chemical Co, produced in *E. coli*) in carboxymethylcellulose was administered to the mice (5/sex) at 5050 mg/kg bw by single oral gavage. A 20% w/v concentration in 2% w/v aqueous carboxymethylcellulose was used, as this was the highest concentration able to be administered through the gavage tube.

Mice were observed for clinical signs at least 3 times on the day of dosing and once daily after this for a 14-day observation period. There did not appear to be any ill effects from the dosing volume. Bodyweight was determined predosing (day 0) and on days 7 and 14. At the end of the study, mice were killed for postmortem examination of gross pathology. Any abnormalities were recorded and the gastrointestinal tracts were preserved in formalin for later histopathological examination if required.

There were no deaths during the study. The only abnormal clinical sign observed in the test group was piloerection (hair standing on end), which occurred only on day 1. During the second week after dosing, one female in the test group lost weight; all other mice showed normal bodyweight gains for their age and sex. No abnormalities were detected on necropsy. The acute oral LD<sub>50</sub> for Cry1A(b)  $\delta$ -endotoxin in mice is therefore 70% of 5050 mg/kg bw (ie 3535 mg/kg bw given that the protein was 70% pure). These results are consistent with other studies on the acute toxicity of Cry1A(b) in mice and in rabbits (Noteborn *et al* 1995, Sanders *et al* 1998) and do not demonstrate any potential mammalian toxicity from Cry1A(b) protein.

#### 4.2.2 *PAT*

(i) *History of consumption*

The *pat* gene encodes the phosphinothricin-N-acetyl transferase enzyme which has a very narrow substrate specificity for phosphinothricin and demethyl-phosphinothricin, both of which are not found in humans. Acetyl transferases are a class of enzymes common to all bacterial, plant and animal cells and play a major role in both the synthesis and oxidation of fats. Since proteins from this family are naturally present in virtually all cells, they can be considered a component of the human diet.

(ii) *Similarity with known toxins*

A comparison of the amino acid sequence of the PAT protein to a database of known toxins demonstrated that it does not share any significant similarity with any known protein toxins. The sequences were obtained from the GenBank, EMBL, Swissprot and PIR databases. Additionally, no reports were found of toxicity associated with acetyl transferases as a class and that the donor organism has no known pathogenic potential.

(iii) *Equivalence of the plant PAT protein to the bacterially produced protein.*

PAT expression was at the limit of detection in Bt-11 corn plants and it was not possible to extract it in sufficient quantities to be used in model digestion system or oral toxicity studies or

to be compared to the bacterially produced protein. The PAT protein was therefore derived from expression of the recombinant protein in *E. coli*. However, the modified *pat* gene transferred to corn plants produces a protein of 183 amino acids, the sequence of which is identical to that of the PAT protein encoded by the native *pat* gene.

Based on the *pat* gene construct, there is no reason to expect that the plant produced PAT protein would be different in any way to the bacterially produced PAT protein.

(iv) *Equivalence of the PAT protein produced by the bar gene.*

Phosphinothricin acetyl transferase is also produced by *Streptomyces hygroscopicus* (Thompson *et al*, 1987) which is encoded for by the *bar* gene. A functional and structural comparison of both protein products has concluded that both proteins have comparable molecular weights and show similar immuno-cross-reactivity to their respective polyclonal antisera (Wehrmann *et al*, 1996). Both enzymes have a similar substrate affinity (for L-phosphinothricin) and do not acetylate any of the other L-amino acids tested. Both proteins were rapidly broken down in model digestion system studies and had decreased enzymatic activity (Wehrmann *et al*, 1996). These studies are discussed in the next part and also under Section 4.4.

(v) *Acute oral toxicity in mice – bacterially produced PAT*

Hsd:S-D ICR albino mice (source: Harlan Sprague Dawley Inc, Texas) were housed individually in controlled conditions with free access to food and water, except for the 16 hours before dosing when food was withheld. Groups (5/sex) of mice were given a single oral dose (gavage) of PAT protein (PAT-0195, purity 51% phosphinothricin acetyltransferase, expressed by the *bar* gene in *E. coli*) in carboxymethyl cellulose; heat inactivated PAT (PAT-0195C, 52% purity) in carboxymethyl cellulose; or carboxymethyl cellulose to a total dose of protein of approximately 2600 mg/kg bw (ie 51-52% of 5050 mg/kg bw, given that this was the purity of the protein).

Mice were observed for clinical signs at least 3 times on the day of dosing and once daily after this for a 14-day observation period. Bodyweight was determined predosing (day 0) and on days 7 and 14. At the end of the study, mice were killed for postmortem examination of gross pathology.

One male receiving the test substance died during the study. The only notable clinical signs were decreased activity, piloerection and ptosis (drooping eyelid) on days 6–8 in the male that died. One male receiving the reference substance showed slight piloerection on the day of dosing. However, as no other clinical signs were observed in animals of any group, these signs are not considered to be treatment related. Bodyweight gain was unaffected by treatment, except in the male that died. There were no abnormal findings on postmortem of animals surviving until the end of the study. The results do not indicate any potential toxicity from the PAT protein.

### **4.3 Levels of naturally-occurring allergenic proteins**

Corn does not contain any known naturally-occurring allergens (Wright 1987).

### **4.4 Potential allergenicity of novel proteins**

Although there are no simple predictive assays available to assess the allergic potential of proteins, a number of characteristics are common among many of the allergens that have been

characterised. For instance, amino acid sequence similarity with known allergens may be a useful gauge of allergenic potential. A string of 8-12 consecutive amino acid residues in common with known allergens could be an indicator for allergenicity given that many T-cell epitopes of allergenic proteins are that length (Taylor and Lehrer, 1996). In terms of the chemical and physical nature of proteins, known allergens tend to be glycosylated proteins with a molecular weight of 10–70 kDa (Lehrer *et al*, 1996). Allergens also tend to be heat stable as well as resistant to peptic and tryptic digestion and the acidic conditions of the stomach. Consequently, many allergenic factors tend to be resistant to proteolytic digestion (Taylor and Lehrer, 1996). The Cry1A(b) and PAT proteins are evaluated for potential allergenicity against these criteria: molecular size, amino acid sequence similarity to known allergens, and how easily the protein is degraded by heat, acid and gastric enzymes (Lehrer and Reese 1998, Jones and Maryanski 1991).

Novartis submitted three studies relevant to the possible allergenicity of the novel proteins which are listed below. The *in vitro* digestibility of the proteins was investigated to consider the potential allergenicity of the novel protein products which can be related to the presence of large undigested protein molecules.

Studies submitted by Novartis:

Privalle L (1994). *In vitro* digestibility of Cry1A (b) protein from Bt maize (corn) and *Bacillus thuringiensis* subspecies *kurstaki* under simulated mammalian gastric conditions. Ciba Seeds. Agricultural Biotechnology Research Unit, Ciba-Geigy Corporation, Research Triangle Park, NC, USA.

Privalle L (1994). *In vitro* digestibility and inactivation of the bar marker gene product phosphinothricin acetyltransferase (PAT) under simulated mammalian gastric conditions. Ciba Seeds. Agricultural Biotechnology Research Unit, Ciba-Geigy Corporation, Research Triangle Park, NC, USA.

Meeusen R. and Mettler I. (1994), revised by Goy P.A. (1998). Equivalence of plant and microbially produced *Bacillus thuringiensis* subsp. *kurstaki* HD-1 protein. Performing laboratories: Novartis Seeds/Northrup King Co, University of Wisconsin, Kendrick Laboratories and Washington University School of Medicine, USA.

#### **4.4.1 Cry1A(b) protein**

As described in Section 3, the Cry1A(b) protein produced by Bt-11 corn was demonstrated to be equivalent to the microbially-produced protein in terms of the N-terminal sequence, immunoreactivity and post-translational modification. The microbially-produced protein is considered to be a suitable substitute for plant-expressed Cry1A(b) for allergenicity studies.

##### *(i) Physical properties of the protein*

The Cry1A(b) core protein has a molecular weight of 63 kDa, which is in the size range of known allergens.

The amino acid sequence of the Cry1A(b) protein was compared to the amino acid sequences of 219 known allergens present in public domain databases (eg GenBank, EMBL, Swissprot, PIR). No biological similarity was found with any of these known allergens.

##### *(ii) Model digestive system studies*

Native Cry1A(b) protein obtained from *Bacillus thuringiensis* subsp *kurstaki* was digested under simulated gastric conditions. The protein was extracted from a cell paste of *Btk* strain HDI-9.

Simulated gastric fluid (SGF) was prepared containing NaCl, HCl and pepsin. The pepsin content (X) was initially 3.2 mg/mL, with a pH of 1 to 1.2. Solutions of SGF containing dilutions of pepsin (0.1, 0.01 and 0.001 times the standard dilution) were also prepared to investigate the degradation of the protein over time. Gastric fluid without pepsin was also prepared.

In an initial trial, 10 µL of protein sample (100 µg of protein) was added to 90 µL of SGF. A 50 µL aliquot was immediately removed, neutralised and heated to 75°C for 10 minutes. The remainder was incubated at 37°C for 2 minutes before neutralising and heating. Following the initial trial, a trial to investigate the time course of degradation was performed using 0.01X pepsin solution. 40 µL of protein sample was added to 360 µL of SGF. 50 µL was removed at 0, 1, 2, 5, 10 and 30 minutes and neutralised and heated as above. The protein content of each sample (in the initial and time course trial) was analysed by western blot.

Following incubation with a solution containing a standard quantity of pepsin, the native Cry1A(b) protein was almost all degraded after 2 minutes. In the time course trial, the protein was undetectable after 5 minutes with 0.01 times the standard dilution of pepsin.

This trial using simulated gastric conditions indicates that Cry1A(b) protein obtained directly from *Bacillus thuringiensis* subsp *kurstaki* is digested as normal dietary protein, being rapidly degraded under simulated gastric conditions. This result is consistent with published studies (Noteborn *et al* 1995, Sanders *et al* 1998). As Cry1A(b) produced by Bt-11 was found to be identical to the microbially produced protein (as discussed in Section 3), it can be concluded that the Bt-11 Cry1A(b) would rapidly degrade in the digestive tract. As Cry1A(b) is present at low levels in the kernel, is easily digested and does not show any amino acid sequence similarity with known allergens, it is not considered to be allergenic.

#### **4.4.2 PAT protein**

##### *(i) Physical properties of the protein*

A comparison of the amino acid sequence of the PAT protein to a database of known allergens demonstrated that it does not share any significant similarity with any known protein allergens. Additionally, acetyltransferases in general have no similarity to any reported mammalian allergens.

##### *(ii) Model digestive system studies*

The PAT protein used in this trial was obtained from an *E. coli* expression system and was purified following fermentation. SGF contained NaCl (2 mg/mL), HCl and pepsin (3.2 mg/mL), the pH was 1.0 to 1.2, and the activity of the fluid was determined before use. Solutions were prepared containing successive dilutions of pepsin (0.1, 0.01 and 0.001 times the standard dilution). The reactions were started by adding 10 µL to PAT sample (26 µg total protein) to 90 µL of the appropriate gastric solution. After mixing, 50 µL was removed, neutralised and heated. This sample was designated the time zero sample. The remainder was incubated for 2 minutes before neutralisation and heating. The presence of PAT in the fluid following incubation was determined by SDS-PAGE analysis. The enzymic activity of the solution was also determined at the pH optimum for the enzyme, at gastric pH and following serial incubation with a gastric solution containing 0.0032 mg/mL pepsin.

In the presence of SGF containing a standard concentration of pepsin, the PAT protein was completely degraded at time zero. After 2 minutes of incubation with 0.1 or 0.01 times the standard pepsin concentration, PAT degradation appeared complete. When 0.001 times the standard concentration was used, a significant amount of PAT remained after a 2-minute incubation period. This concentration was thus selected for the enzyme inactivation studies.

The enzyme activity of PAT decreased to 56% of initial values after a 10-minute incubation at 37°C. This reflects the thermal sensitivity of the enzyme above 35°C, and would represent the maximum activity were gastric pH or pepsin to have no effect on PAT activity. Immediately after addition to SGF without pepsin, PAT activity decreased to 2.6% of the initial activity, and reached zero by 1 minute. When pepsin was included in the SGF, the initial activity was even lower. Activity was not restored by neutralisation, indicating that inactivation of the PAT enzyme was irreversible. The half-life of the PAT protein in SGF containing 0.0032 mg/mL was between 1 and 2 minutes.

This study demonstrates that PAT loses enzymatic activity immediately upon exposure to gastric pH, and that the protein is readily digested in the stomach. As the PAT protein is present at low levels in the kernel, is easily digested and does not show amino acid sequence similarity with known allergens, it is considered highly unlikely to be allergenic.

#### **4.5 Conclusions regarding toxicological issues**

Analysis of the physical and chemical properties of the Cry1A(b) and PAT proteins have not revealed any similarities to known toxins and allergens. No adverse reactions were observed in mice that were administered either protein in acute toxicity tests. No evidence suggests that either protein has been derived from a potentially toxic or allergenic source and the Cry1A(b) protein has a long history of safe use. Both proteins are present in corn kernels at low levels and are shown to degrade in conditions that mimic the human digestive system. Therefore it is highly unlikely that either the Cry1A(b) or PAT protein would be toxic or allergenic to humans.

### **5. NUTRITIONAL ISSUES**

#### **5.1 Nutrient analysis**

The safety assessment includes an analysis of the composition of the food in comparison with other commercial varieties of the crop. Given that food is produced from many corn varieties, the applicant has provided data on several different dent and sweet corn varieties. Refer to Table 2 for a complete summary of the lines analysed.

Four major studies have been conducted on Bt-11 kernels that assess the major components in inbred and hybrid lines at different stages of maturity and a comparison with their respective near-isogenic controls. The first study is an analysis of the glasshouse grown original transformant. The second suite of studies have been conducted on six dent corn lines developed from conventional breeding with the original transformant. The third set of data has been provided on sweet corn lines also derived from conventional breeding with the original transformant. A final study assesses the potential effect of Bt-11 corn treated with the herbicide glufosinate ammonium during growing.

Studies submitted by Novartis:

Compositional analysis of Bt11 maize: determination of the substantial equivalence — chemical composition analysis done with Bt-11 maize with a European background. Performing laboratory: Association Generale des Producteurs de Mais).

Compositional analysis of Bt11 maize: determination of the substantial equivalence — chemical composition analysis done with Bt-11 maize with a US background. Part 1: Properties of grain produced from ECB protected maize hybrids; Part 2: Characterization of grain attributes of normal, wild-type maize hybrids and the Bt11 converted iso-hybrid counterparts; Part 3: Analyses of fatty acid and amino acid profiles of grain from Bt-11 maize. Report No. NSB-004-97. Performing laboratory: Novartis Seeds/Northrup King Co.

Comparison of nutritional composition of fresh and canned grain prepared from Attribute insect protected and control sweet corn hybrids. Report No. NSV-002-98. Novartis Seeds Inc.

Comparison of vitamin and mineral composition of Bt11 maize and non-modified maize hybrids. Report No. NSB-004-97. Novartis Seeds.

Goy P.A. (1999). Novartis Seed's genetically modified Bt11 maize: biochemical composition of kernels from plants treated with a glufosinate ammonium herbicide.

### ***5.1.1 Study 1: Analysis of Bt-11 corn grown in greenhouses in Europe***

The following greenhouse grown plants were analysed: an inbred line (H8540-Bt), a hybrid line (hybrid Bt<sup>+</sup>/Bt<sup>-</sup>) and their respective controls (isogenic non-modified H8540 and control hybrid). Between 45 and 56 ears were taken from each plant. Ears were harvested and dried four months after sowing and 500 g samples were analysed for moisture, total nitrogen, ash, starch, cellulose, xanthophyll, fat composition and amino acid composition. Statistical comparison with STAT-ITCF software was made on the values of two replicate analyses, except in the case of xanthophyll, fatty acids and amino acids, where data points are the result of a single analysis.

#### *(i) Compositional analyses*

All values for chemical composition were within the normal range for data obtained by the Association Générale des Producteurs de Mais (AGPM), except for total nitrogen, which was higher than normal for both the control and genetically modified corn plants (Table 6).

**Table 6: Summary of compositional analysis for Bt-11 and control corn plants<sup>1</sup>.**

	<b>Inbred line H8540-Bt</b>	<b>Isogenic control H8540</b>	<b>Hybrid Bt+/Bt-</b>	<b>Control hybrid</b>	<b>Normal range<sup>2</sup></b>
Total nitrogen <sup>3</sup>	13.18 ± 0.07	12.35 ± 0.06	12.28 ± 0.03	12.30 ± 0.07	7.7–10 <sup>4</sup>
Moisture	12.3	12.6	12.6	13.3	7–23
Ash	1.47 ± 0.04	1.79 ± 0.007	1.70 ± 0.02	1.6 ± 0.02	1.1–3.9
Starch	68.02 ± 0.4	67.57 ± 0.4	70.83 ± 0.81	70.25 ± 0.48	61–78
Cellulose	2.99 ± 0.007	2.9 ± 0.05	2.67 ± 0.28	2.92 ± 0.05	3.3–4.3 1.93–2.5 <sup>4</sup>
Xanthophyll	24.2	21.0	21.6	19.1	19.2–33.1 <sup>4</sup>

<sup>1</sup>Samples are 500g of kernels from: Bt<sup>+</sup>/Bt<sup>+</sup> H8540 ears n=54, Control H8540 n=56, Bt<sup>+</sup>/Bt<sup>-</sup> hybrid n=50, Control hybrid ears n= 45. Each data point represents the mean of two replicate analyses made with the 500g sample. Data from AGPM. All data except moisture (% H<sub>2</sub>O) and xanthophyll (mg/kg dry weight basis) are presented on a % dry weight basis.

<sup>2</sup>Wright, 1987 in Corn chemistry and technology, 1987, Watson SA and Ramstad PE (eds), American Association of Cereal Chemists, St. Paul, Minnesota, USA.

<sup>3</sup>All values from control and genetically modified lines are significantly different to range.

<sup>4</sup>Data from AGPM

Protein levels were higher than the normal range for all plants assessed. As protein content is affected by soil nitrogen, it is possible that the fertiliser used in culturing the plants caused the high level of nitrogen for all plants in the study.

(ii) *Amino acid analysis*

A summary of amino acid values for plants homozygous for the *cry1A(b)* gene is shown in Table 7. A single analysis was done on 500g samples of kernels from Bt<sup>+</sup>/Bt<sup>+</sup> H8540 (number of ears n=54), isogenic control H8540 (number of ears n=56), Bt<sup>+</sup>/Bt<sup>-</sup> hybrid (number of ears n=50), control hybrid (number of ears n= 45). Values for amino acid composition (once corrected for the high total nitrogen) had minor variations to control values but were within the normal range according to APGM and the published literature. There were no differences in these values greater than 10% (which allows for experimental error) between the modified corn and isogenic controls. The levels of glutamine, asparagine, tryptophan were not determined. No spectrum or literature ranges were available for some of the amino acids, as some of these analyses are not routinely carried out by the laboratory assaying these samples.

**Table 7: Summary of amino acid composition data for Bt-11 corn plants<sup>1</sup>.**

Amino acid composition	Bt <sup>+</sup> /Bt <sup>+</sup> line H8540	Control H8540	Bt <sup>+</sup> /Bt <sup>-</sup> hybrid line	Control hybrid line	Range <sup>2</sup>
Aspartic acid	9.8	9	8.7	8.4	
Threonine	5.2	5	4.9	5	3.2–3.4
Serine	6.6	6.4	6.1	6.1	
Glutamic acid	28.1	25.7	26.2	25.1	
Proline	12	12.5	12	11.4	
Glycine	4.1	4.2	4	4	
Alanine	11.5	10.8	10.8	10.1	
Cysteine	2.4	2.4	2.5	2.7	
Valine	6.5	6.1	5.9	6.2	4.2–4.6
Methionine	2.5	2.5	2.7	2.9	1.8–1.9
Isoleucine	5.2	4.8	4.6	4.6	3.4–3.7
Leucine	19.4	17.5	17.7	17.3	10–11.3
Tyrosine	5.4	4.9	5	4.7	
Phenylalanine	7.2	6.5	6.4	6.3	4.4–4.5
Lysine	3.2	3.3	3.1	3	2.45–2.6
Histidine	3.5	3.4	3.4	3.5	
Arginine	4.4	4.8	4.9	4.8	4.1–5.2

<sup>1</sup>Values are expressed as g/Kg dry matter.

<sup>2</sup>Data from L'alimentation des animaux monogastriques: porc, lapin, volailles. INRA 1989, Feedstuffs ingredient analysis table, edition 1996, AEC Table and 1995 UCAAB data.

(iii) *Fatty acid analysis*

A summary of fatty acid values for plants homozygous for the *cry1A(b)* gene is shown in Table 8. A single analysis was done on 500g samples of kernels from Bt<sup>+</sup>/Bt<sup>+</sup> H8540 (number of ears n=54), isogenic control H8540 (number of ears n=56), Bt<sup>+</sup>/Bt<sup>-</sup> hybrid (number of ears n=50), control hybrid (number of ears n= 45). Values for fatty acid composition had minor variations to control values but were within the normal range according to APGM and the published literature. There were no differences in these values greater than 10% (which allows for experimental error) between the modified corn and controls. Literature ranges were available for most of the common fatty acids and not the minor ones as analyses of these fatty acids are not routinely carried out.

**Table 8: Summary of fatty acid composition data for Bt-11 corn plants<sup>1</sup>.**

Fatty acid composition	Bt <sup>+</sup> /Bt <sup>+</sup> line H8540	Control H8540	Bt <sup>+</sup> /Bt <sup>-</sup> hybrid line	Control hybrid line	Range
C16 palmitic acid	15.1	14.5	15.3	14.6	6–22 <sup>2</sup>
C18 stearic acid	1.7	1.6	1.6	1.5	1–15 <sup>2</sup>
C18:1 oleic acid	20.6	21.9	21.8	21.8	14–64 <sup>2</sup>
C18:2 linoleic acid	58.9	58.2	58.1	60	19–71 <sup>2</sup> ; 56–65 <sup>3</sup>
C18:3 linolenic acid	1.7	1.7	1.2	1.1	0.5–2 <sup>2</sup>
C20 arachidic acid	0.5	0.4	0.4	0.4	
C20:1 gadoleic acid	0.2	0.2	0.2	0.2	
C22: behenic acid	0.2	0.2	0.1	0.1	

<sup>1</sup>Samples are 500g of kernels from: Bt<sup>+</sup>/Bt<sup>+</sup> H8540 ears n=54, Control H8540 n=56, Bt<sup>+</sup>/Bt<sup>-</sup> hybrid n=50, Control hybrid ears n= 45. Values are expressed as % of the analysed fatty acid relative to the total amount of fatty acids.

<sup>2</sup>From Weber, "Lipids of the kernel", Chapter 10 in Corn chemistry and technology, 1987, Watson SA and Ramstad PE (eds), American Association of Cereal Chemists, St. Paul, Minesota, USA. data

<sup>3</sup>AGPM

## 5.1.2 Study 2: Analysis of Bt-11 dent corn grown in USA

### 5.1.2.1 Data set 1

An analysis of the major components and nutritional qualities of elite Bt-11 dent corn lines has also been assessed. These lines are derived from the original transformant. Two genetically modified Bt-11 hybrid corn lines and their near-isogenic controls were grown in three field locations in the USA in 1995. Kernels were analysed for percentage of starch, protein, oil and fibre. These components were estimated by near infrared reflectance (NIR) spectroscopy by the Illinois Crop Improvement Association Inc. NIR analyses are methods used by the American Association of Cereal Chemists.

The kernels from insect-protected corn hybrids were comparable to control hybrids for percentage starch, protein, oil and fibre (Table 9) and fell within the normal ranges expected for these components.

<sup>2</sup>From Corn chemistry and technology, 1987, Watson SA and Ramstad PE (eds), American Association of Cereal Chemists, St. Paul, Minnesota, USA.

<sup>3</sup>Average value

**Table 9: Summary of compositional analysis for Bt-11 and control corn plants<sup>1</sup>.**

	X6534CBR	Isogenic control X6514	X7634CBR	Isogenic control X7514	Normal range <sup>2</sup>
Protein	9.89 (9.40-10.60)	9.96 (9.10-11.40)	10.55 (10.24-11.00)	9.68 (8.90-10.94)	6-12
Oil	4.09 (4.00-4.16)	4.11 (4.10-4.13)	4.02 (4.00-4.02)	4.07 (3.80-4.31)	3.1-5.7
Starch	70.09 (68.80-71.07)	70.19 (67.80-71.50)	69.32 (68.60-70.36)	70.36 (69.07-71.40)	61-78
Fibre	2.95 (2.86-3.00)	2.97 (2.92-3.00)	2.93 (2.89-3.0)	2.91 (2.90-2.92)	2.5 <sup>3</sup>

<sup>1</sup>Values presented as % dry weight. Values are means of 3 samples taken from 3 locations (ie 1 sample/location), ranges are given in brackets. Genetically modified corn lines are denoted CBR and are isogenic to their controls except for the presence of the novel genes.

### 5.1.2.2 Data set 2

A second nutritional study on Bt-11 dent corn that included additional hybrids was done. Three to five ears were picked from the centre two rows of a four row strip plot for each hybrid per two sites within three geographical regions to give a total of six locations per hybrid. Two of the hybrids are 'northern' (early-season) hybrids and two were 'southern' (mid-late-season) hybrids and were grown with their respective isogenic controls. The grain was analysed by the Illinois Crop Improvement Association using Near Infrared Reflectance Spectroscopy (NIRS) according to methods of the American Association of Cereal Chemists.

#### (i) Compositional analyses

The compositional data for the Bt-11 corn (denoted as corn borer resistant – CBR) and control corn plants were analysed for significant differences by Analysis of Variance (SAS GLM procedure). The components measured were % protein, oil, starch and fibre (Table 10). Kernels

from the early season (northern hybrids) genetically modified corn hybrids (X4334CBR and X4734CBR) have a significantly lower protein content than kernels from the control corn lines (P=5 and P=1 respectively). All other components were comparable between the Bt-11 corn hybrids and their respective control corn lines.

**Table 10: Summary of compositional analysis for Bt-11 and control corn plants from a second field trial<sup>1</sup>.**

<b>Northern / Early</b>	<b>X4334CBR</b>	<b>Control N4242</b>	<b>X4734CBR</b>	<b>Control N4640</b>	<b>Normal range<sup>2</sup></b>
Protein	8.65 <sup>3</sup> (8.03-9.11)	9.25 (8.63-9.63)	8.19 <sup>4</sup> (7.74-9.16)	8.96 (8.28-9.53)	6-12
Oil	3.17 (2.81-3.73)	3.23 (3.04-3.50)	3.34 (3.36-3.48)	3.30 (3.12-3.68)	3.1-5.7
Starch	72.93 (71.8-73.2)	72.57 (71.7-73.4)	72.73 (71.5-73.7)	72.62 (71.3-73.2)	61-78
Fibre	2.69 (2.66-2.83)	2.75 (2.67-2.93)	2.77 (2.68-2.83)	2.77 (2.69-2.83)	2.5 <sup>5</sup>
<b>Southern / Mid-late</b>	<b>X6534CBR</b>	<b>X6514</b>	<b>X7634CBR</b>	<b>X7514</b>	
Protein	9.52 (8.35-10.60)	9.93 (9.10-11.40)	9.85 (8.63-11.00)	9.87 (8.67-10.94)	6-12
Oil	3.80 (3.63-4.16)	3.93 (3.27-4.13)	3.37 (2.59-4.00)	3.48 (2.70-4.31)	3.1-5.7
Starch	70.77 (68.8-72.5)	71.07 (67.8-72.7)	71.33 (68.6-74.3)	71.12 (69.1-73.9)	61-78
Fibre	2.78 (2.55-3.00)	2.80 (2.61-3.0)	2.74 (2.53-3.00)	2.72 (2.46-2.92)	2.5 <sup>5</sup>

<sup>1</sup>Values presented as % dry weight. Values are means of a total of 6 samples taken from 2 sites in 3 locations (ie 2 distinct samples from each of the 3 locations), ranges are given in brackets.

<sup>2</sup>From Corn chemistry and technology, 1987, Watson SA and Ramstad PE (eds), American Association of Cereal Chemists, St. Paul, Minesota, USA.

<sup>3</sup>Values are significantly different to that of control value at 5% level of probability.

<sup>4</sup>Values are significantly different to that of control value at 1% level of probability.

<sup>5</sup>Average value

The “northern” and “southern” hybrids were derived from separate backcross conversion processes using the same original transformation event (plant). Although the protein was lower in the northern hybrids, there is a lack of consistent differences between the non-modified hybrids and their genetically modified equivalents. This may indicate that the effects observed, are not likely to be a result of the genetic modification itself but more likely from differences arising out of an incomplete backcross conversion in the normal breeding process. Values for all the parameters measured fell within the ranges cited in the literature (refer to Table 10).

## (ii) Amino acid analyses

Amino acid analyses were performed on kernels obtained from two Bt-11 hybrid corn lines: X6534CBR (a mid-late maturity variety) and X4734CBR (an early maturity variety) and their genetically equivalent controls (N6800 and N4640 respectively). The kernels were sampled from two locations, three samples per line. For further comparison, kernels from another seven non-modified reference hybrids were grown in one of the field trial locations (N4242, N5220, N5866, N6223, N6822, N7070 and N790). Two separate statistical analyses were performed — the first to analyse the variation between hybrids to determine whether there were significant differences between hybrids. The second study analysed differences specifically between genetically modified hybrids and their near-isogenic controls (Table 11).

The first statistical analysis determined the variation between hybrids. Since not all hybrids were replicated, the analysis used the variation observed in hybrids with multiple replicates as an indication of “error” for the other hybrids. The rationale for this is that other hybrids would have been equally variable. There were significant differences between the hybrids for all values except that for tyrosine (P=5).

Small but significant differences at the 5% level were found between the genetically modified corn hybrid X4734CBR and its control line N4640 for arginine and cysteine. This difference is not consistent for all genetically modified corn hybrids and is consistent with the variability that is observed between lines. Some variability may arise as a result of incomplete backcrossing. This variation is not considered to be a result of the genetic modification nor is it biologically significant.

(iii) *Analysis of fatty acid profiles*

Fatty acid analyses were also done on the kernels sampled as described above. The kernels were sampled from two locations, three samples per line from two Bt-11 hybrid corn lines X6534CBR and X4734CBR and their genetically equivalent controls (N6800 and N4640 respectively). Additionally, grain from another seven non-modified reference hybrids were also analysed. As outlined above for the amino acid analysis, two separate statistical analyses were performed — the first to analyse the variation between hybrids to determine whether there were significant differences between hybrids. The second study analysed differences specifically between genetically modified hybrids and their isogenic controls. The results are shown in Table 12.

A statistical analysis to determine the variation between hybrids, as described above for the amino acid analysis, found no significant differences between the hybrids for fatty acid values (P=5).

**Table 11: Amino acid profile for Bt-11 hybrids and control corn plants<sup>1</sup>.**

	<b>X6534-CBR</b>	<b>N6800</b>	<b>X4734-CBR</b>	<b>N4640</b>	<b>N4242<sup>4</sup></b>	<b>N5220<sup>5</sup></b>
Tryptophan	0.05-0.06	0.05-0.06	0.05 <sup>2</sup>	0.05-0.06	0.05 <sup>2</sup>	0.07
Aspartic Acid	0.61-0.67	0.60-0.66	0.54 <sup>2</sup>	0.55-0.57	0.55 <sup>2</sup>	0.64
Threonine	0.35-0.38	0.35-0.38	0.29-0.30	0.30-0.31	0.30-0.32	0.36
Serine	0.50-0.55	0.50-0.55	0.42-0.43	0.43-0.44	0.43-0.44	0.52
Glutamic Acid	1.54-1.72	1.55-1.79	1.17-1.25	1.22-1.30	1.30-1.32	1.63
Proline	0.77-0.88	0.83-0.91	0.68-0.70	0.63-0.68	0.61-0.66	0.84
Glycine	0.34-0.37	0.35 <sup>2</sup>	0.29-0.30	0.31-0.33	0.32-0.34	0.36
Alanine	0.75-0.82	0.75-0.87	0.60-0.62	0.58-0.63	0.61-0.63	0.74
Cysteine <sup>3</sup>	0.21-0.22	0.22-0.23	0.17 <sup>2</sup>	0.20-0.21	0.18-0.21	0.22
Valine	0.41-0.43	0.40-0.45	0.32-0.33	0.32-0.34	0.32-0.36	0.43
Methionine	0.19-0.21	0.19-0.22	0.17-0.20	0.20-0.23	0.19-0.21	0.24
Isoleucine	0.28-0.32	0.28-0.33	0.23-0.25	0.24-0.26	0.23-0.27	0.32
Leucine	1.23-1.37	1.23-1.45	0.93-0.98	0.96-0.98	0.92-1.01	1.32
Tyrosine	0.14-0.18	0.14-0.16	0.13 <sup>2</sup>	0.13-0.14	0.14 <sup>2</sup>	0.17
Phenylalanine	0.44-0.49	0.44-0.51	0.37-0.39	0.36-0.40	0.35-0.38	0.50
Histidine	0.32-0.35	0.34-0.37	0.26-0.27	0.28-0.29	0.27-0.28	0.31
Lysine	0.25-0.26	0.24-0.26	0.23-0.24	0.24-0.25	0.23-0.25	0.27
Arginine <sup>3</sup>	0.36-0.37	0.37-0.38	0.31-0.32	0.32-0.34	0.33 <sup>2</sup>	0.39

**Table 11: continued.**

	<b>N5866<sup>5</sup></b>	<b>N6223<sup>5</sup></b>	<b>N6822<sup>5</sup></b>	<b>N7070<sup>5</sup></b>	<b>N7590<sup>5</sup></b>	<b>Range<sup>6</sup></b>
Tryptophan	0.06	0.07	0.06	0.06	0.08	
Aspartic Acid	0.58	0.68	0.59	0.71	0.67	
Threonine	0.34	0.38	0.34	0.40	0.39	0.32-0.34
Serine	0.47	0.55	0.45	0.53	0.56	
Glutamic Acid	1.54	1.83	1.53	1.61	1.83	
Proline	0.77	0.93	0.79	0.75	1.03	
Glycine	0.34	0.36	0.33	0.40	0.36	
Alanine	0.73	0.85	0.70	0.90	0.83	
Cysteine	0.22	0.22	0.20	0.21	0.23	
Valine	0.40	0.45	0.39	0.48	0.47	0.42-0.46
Methionine	0.23	0.26	0.24	0.27	0.34	0.18-0.19
Isoleucine	0.31	0.35	0.30	0.33	0.34	0.34-0.37
Leucine	1.24	1.46	1.20	1.28	1.47	0.10-0.11
Tyrosine	0.15	0.17	0.16	0.15	0.16	
Phenylalanine	0.47	0.54	0.46	0.46	0.54	0.44-0.45
Histidine	0.31	0.35	0.30	0.37	0.32	
Lysine	0.26	0.26	0.25	0.32	0.25	0.25-0.26
Arginine	0.36	0.40	0.36	0.36	0.38	0.41-0.52

<sup>1</sup>Values are ranges for three samples taken from 3 field sites (ie 1 sample/site) and are expressed as g/100g dry weight.

<sup>2</sup>The same value was obtained for all three samples.

<sup>3</sup>Values for genetically modified corn plants are significantly different to those of control corn plants.

<sup>4</sup>Range is obtained from two values

<sup>5</sup>Single value only.

<sup>6</sup>Data from L'alimentation des animaux monogastriques: porc, lapin, volailles. INRA 1989, Feedstuffs ingredient analysis table, edition 1996, AEC Table and 1995 UCAAB data.

**Table 12: Fatty acid profile for Bt-11 hybrids and control corn plants<sup>1</sup>.**

	<b>Palmitic</b>	<b>Stearic</b>	<b>Oleic</b>	<b>Linoleic</b>	<b>Linolenic</b>
X6534CBR	10.99-11.14	1.99-2.16	27.15-27.36	56.88-57.31	1.16-1.25
N6800	10.78-11.11	2.11-2.24	26.85-26.90	56.81-57.07	1.29-1.43
X4734CBR	10.76-10.97	2.38-2.41	25.93-26.04	57.62-57.86	1.61-1.67
N4640	10.61-10.65	2.45-2.52	26.31-27.06	56.69-57.59	1.56-1.59
N4242 <sup>2</sup>	10.76-11.27	2.15-2.31	25.51-25.89	57.32-57.85	1.59-1.66
N5220 <sup>3</sup>	13.14	1.89	26.55	55.13	1.40
N5866 <sup>3</sup>	9.17	2.18	21.05	64.53	1.28
N6223 <sup>3</sup>	11.53	2.01	26.58	57.04	1.24
N6822 <sup>3</sup>	12.05	2.27	18.79	64.30	1.18
N7070 <sup>3</sup>	10.11	1.77	25.49	59.77	1.19
N7590 <sup>3</sup>	9.86	2.17	20.59	64.68	1.18
Range <sup>4</sup>	6-22	1-15	14-64	19-71 56-65 <sup>5</sup>	0.5-2

<sup>1</sup>Values are ranges for three samples taken from 3 field sites (ie 1 sample/site) unless otherwise indicated and are expressed as % of fatty acid as a proportion of total fatty acid.

<sup>2</sup>Values are the range for two samples.

<sup>3</sup>Single values given only.

<sup>4</sup>From Weber, "Lipids of the kernel", Chapter 10 in Corn chemistry and technology, 1987, Watson SA and Ramstad PE (eds), American Association of Cereal Chemists, St. Paul, Minnesota, USA. data

<sup>5</sup>Data from AGPM.

A second statistical analysis of the fatty acid values investigated specifically differences between the genetically modified corn hybrid plants versus the non-modified control hybrids. Small but significant differences at the 5% level were observed for palmitic acid (higher in the genetically modified corn line) and stearic acid (lower in the genetically modified corn line). Using the information from the first analysis on the variation that exists between hybrids, the values determined for the Bt-11 hybrids fall within the range determined for the control hybrids. Additionally, all values are within the range reported in the literature (see Table 7).

(iv) *Vitamins and minerals*

One-pound (2.24 kg) samples of grain were taken from each of three locations from two Bt-11 corn hybrids N4242-Bt and N4640-Bt and their corresponding near-isogenic non-modified hybrids and analysed for their vitamin and mineral content. The grain was analysed for the minerals copper, magnesium, manganese and zinc as well as the vitamins folic acid, niacin, vitamin B<sub>1</sub> and vitamin B<sub>2</sub> (Table 13). No significant differences (p=0.05) between Bt-11 corn hybrids and their corresponding control hybrids were observed for any of the selected components.

**Table 13: Vitamin and mineral profile for Bt-11 and control corn plants<sup>1</sup>.**

	<b>N4242Bt</b>	<b>Control N4242</b>	<b>N4640Bt</b>	<b>Control N4640</b>
Copper	0.17 ± 0.06	0.17 ± 0.06	0.20 ± 0.0	0.20 ± 0.0
Magnesium	95.7 ± 1.15	91.7 ± 5.51	90.0 ± 1.73	86.3 ± 4.73
Manganese	0.47 ± 0.06	0.43 ± 0.06	0.40 ± 0.0	0.33 ± 0.06
Zinc	1.93 ± 0.06	2.03 ± 0.29	1.77 ± 0.12	1.70 ± 0.10
Folic acid	0.051 ± 0.010	0.045 ± 0.002	0.57 ± 0.03	0.57 ± 0.03
Niacin	8.62 ± 1.32	8.03 ± 0.14	8.96 ± 0.21	9.49 ± 0.41
B <sub>1</sub>	1.44 ± 0.10	1.37 ± 0.21	1.26 ± 0.23	1.48 ± 0.15
B <sub>2</sub>	0.71 ± 0.04	0.70 ± 0.09	0.72 ± 0.04	0.71 ± 0.02

<sup>1</sup>Values are means of 3 samples, one from each of 3 locations. Minerals are expressed as % and vitamins are expressed in mg/lb.

**5.1.3 Study 3: Comparison of nutritional composition of fresh and canned Bt-11 sweet corn**

A fourth analysis of Bt-11 corn lines was done, specifically to assess the nutritional value of three Bt-11 sweet corn varieties. Corn was harvested from the Bt-11 sweet corn hybrids, Bt 98-0943, Bt 95-0937 and Bt 95-0941, and from their corresponding near-isogenic non-modified hybrids, grown in 1996 at one location in the United States. Ten ears of each of the hybrids were harvested at prime harvest and analysed as fresh corn on the cob. Corn from each hybrid was canned and also analysed (processed corn analysis).

Fresh and canned sweet corn was analysed for moisture, protein, fat, ash, carbohydrates, fibre, vitamins and minerals (Table 14) according to methods from the Association of Official Analytical Chemists. Given that there was only duplicate analysis of the one sample taken for each line, no statistical analysis was performed.

Comparable nutritional composition was observed between the three Bt-11 sweet corn hybrids and their corresponding isogenic hybrids for both the fresh corn and canned corn.

**Table 14: Compositional profile for fresh and canned sweet corn Bt-11 hybrids<sup>1</sup>.**

<b>Fresh</b>	<b>Bt 95-0943</b>	<b>Jubilee</b>	<b>Bt 95-0937</b>	<b>Bonus</b>	<b>Bt 95-0941</b>	<b>Empire</b>
Moisture (g)	69.88 – 69.78	69.67-69.70	73.65	72.20-72.24	71.15-71.28	70.34-70.56
Protein (g)	3.7-4.09	3.20-4.35	3.75-3.37	3.89-4.06	3.75-3.83	4.17-4.26
Fat (g)	0.76-1.34	1.10-0.97	0.75-0.91	0.81-0.88	0.85-1.18	0.91-1.13
Ash (g)	0.90-0.93	0.91	0.99-1.05	1.00-1.03	1.01-1.02	0.91-0.95
Carbohydrates - total <sup>2</sup> (g)	24.28	24.63	20.94	22.06	22.89	23.36
Calories <sup>2</sup>	111	112	93	100	105	110
Calories <sup>2</sup> from fat	10	9	7	7	10	9
Sugars <sup>2</sup> (g)	6.8	6.31	4.14	4.38	5.21	4.86
Other Carbohydrates <sup>2</sup> (g)	14.71	15.59	13.77	15.01	14.81	16.04
Total Dietary Fibre (g)	2.83-2.71	2.93-2.54	2.61-3.44	2.64-2.70	2.36-3.38	2.38-2.54
Vitamin A <sup>2</sup> (IU)	230	137	280	211	95.8	160
Vitamin C <sup>2</sup> (mg)	0.869	1.63	7.35	6.53	7.25	7.69
Sodium (mg)	9.9-14.2	5.9-7.2	10.0-13.0	3.9-5.3	5.8-7.2	4.9-8.6
Potassium (mg)	293.5-286.2	326.0-322.6	287.6-307.4	292.6-306.7	372.7-391.8	255.6-322.9
Calcium (mg)	3.4-8.6	1.6	0.7-7.1	0.0-0.4	7.1-8.0	0.7-7.1
Iron (mg)	0.49-0.85	0.49-0.56	0.57-0.61	0.6-0.90	0.54-0.63	0.71-0.74
<b>Canned</b>	<b>Bt 95-0943</b>	<b>Jubilee</b>	<b>Bt 95-0937</b>	<b>Bonus</b>	<b>Bt 95-0941</b>	<b>Empire</b>
Moisture (g)	77.81 – 77.83	76.81-76.85	77.66-77.76	77.77-77.80	76.44-76.52	77.80-77.96
Protein (g)	2.95-2.99	2.62-2.97	2.95-3.00	3.09-3.18	2.85-2.94	2.93-3.02
Fat (g)	0.85-1.77	1.02-1.90	1.01-1.09	0.68-0.75	0.83-0.96	0.62-0.85
Ash (g)	0.97-1.01	1.01	0.84-0.85	0.85-0.87	0.85-0.87	0.83-0.83
Carbohydrates - total <sup>2</sup> (g)	16.91	17.92	17.42	17.5	18.87	17.59
Calories <sup>2</sup>	83	87	81	79	86	79
Calories <sup>2</sup> from fat	12	13	9	6	8	7
Sugars <sup>2</sup> (g)	1.8	1.92	1.54	1.3	1.89	1.53
Other Carbohydrates <sup>2</sup> (g)	12.99	13.85	13.38	13.72	14.65	13.56
Total Dietary Fibre (g)	1.99-2.23	2.01-2.29	2.47-2.55	2.41-2.54	2.19-2.48	2.18-2.82
Vitamin A <sup>2</sup> (IU)	175	209	192	185	175	206
Vitamin C <sup>2</sup> (mg)	2.07	2.32	2.25	2.31	2.15	1.99
Sodium (mg)	262.8-285.0	266.1-304.1	245.9-248.0	212.5-230.2	225.7-239.6	191.9-235.6
Potassium (mg)	199.9-202.8	212.2-262.4	210.3-228.4	191.4-202.6	181.1-205.3	176.3-200.2
Calcium (mg)	3.1-8.8	2.4-4.2	0.0-1.8	5.1-8.2	3.7-10.2	5.2-8.2
Iron (mg)	0.29-0.55	0.289-0.614	0.31-0.25	0.23-0.34	0.348-0.387	0.31-0.37

<sup>1</sup>Values are expressed per 100 g serving basis.

<sup>2</sup>Only one sample determined.

#### 5.1.4 Study 4: Analysis of Bt-11 dent corn lines treated with herbicide

An additional study was done to assess the potential effects of herbicide treatment on the major components of the corn kernels. Three Bt-11 hybrids representing different maturity types (Madera, Manuel and Magister) and their isogenic controls were grown in open fields at two locations in France in 1998. Proximate analysis (carbohydrate, protein, fat and fibre), fatty acids and amino acid composition were compared between transgenic crops treated with a glufosinate ammonium herbicide (Liberty®) at a rate of 2.25 L/ha active ingredient at the 3 and 6–7 leaf stages and untreated transgenic and isogenic controls (Table 15). Values presented in this experiment are not directly comparable to values for other experiments because they have been performed by a different laboratory using slightly different methods.

##### (i) Compositional analyses

No significant differences in composition were found between the treated Bt-11 corn plants and untreated Bt-11 corn plants nor between the untreated Bt-11 corn plants and the unmodified control corn plants (P=5).

**Table 15: Compositional analyses for Bt-11 hybrids and control corn plants<sup>1</sup>.**

	<b>Treated</b>	<b>Untreated</b>	<b>Control</b>
Energy	1441 ± 37	1430 ± 35	1433 ± 29
Carbohydrate	70.0 ± 2.0	69.5 ± 1.5	68.8 ± 1.5
Protein	7.6 ± 0.9	8.2 ± 0.8	8.4 ± 0.8
Fat	3.3 ± 0.6	3.0 ± 0.6	3.3 ± 0.8
Fibre	8.0 ± 1.0	8.0 ± 0.8	7.7 ± 0.2

<sup>1</sup>Values are means of 3 samples, one from each of the hybrids Madera, Manuel and Magister. Values are all expressed as a % except for energy (KJ/100g). (ii) *Amino acid analysis*

Amino acid levels were also analysed (Table 16a). The values for cysteine and tryptophan were not determined. Using the F test, significantly different values were obtained for glutamic acid, proline, alanine, isoleucine and phenylalanine when comparing all three treatments (treated GM, untreated GM and control) (at the P=5 level). In a comparison of the values for treated Bt11 hybrids to the non-modified control hybrids, only the values for proline and alanine were significantly different (lower in treated Bt-11 hybrids than in the control lines).

A breakdown of the values for proline and alanine for each of the three hybrids is shown in Table 16b. The difference between the treated modified and non-modified line was not consistent for all lines and may be a result of variability between the lines. This difference is not considered to raise safety or nutritional concerns.

**Table 16a: Amino acid analyses for Bt-11 hybrids and control corn plants<sup>1</sup>.**

	<b>Treated</b>	<b>Untreated</b>	<b>Control</b>
Aspartic Acid	4690 ± 406	5033 ± 439	4703 ± 142
Threonine	2690 ± 423	2850 ± 165	2690 ± 423
Serine	3537 ± 353	3750 ± 260	3537 ± 353
Glutamic Acid	14533 ± 1595	16233 ± 1626	15700 ± 625
Proline	6967 ± 1154	8367 ± 234	8590 ± 769
Glycine	3047 ± 238	3187 ± 111	2920 ± 26
Alanine	5057 ± 415	5760 ± 606	5500 ± 207
Valine	2963 ± 552	3327 ± 654	3210 ± 183
Methionine	1030 ± 183	1270 ± 122	1170 ± 30
Isoleucine	1717 ± 315	2320 ± 368	2013 ± 42
Leucine	8153 ± 918	9320 ± 1105	8787 ± 420
Tyrosine	3800 ± 573	4240 ± 455	3957 ± 172
Phenylalanine	3163 ± 440	3540 ± 243	3363 ± 280
Histidine	1867 ± 376	2147 ± 170	1853 ± 169
Lysine	1967 ± 228	2223 ± 228	1967 ± 163
Arginine	3257 ± 319	3443 ± 119	3160 ± 236

<sup>1</sup>Values are means of 3 samples, one from each of a different maturity type. Values are all expressed as mg/kg.

<sup>2</sup>Data from L'alimentation des animaux monogastriques: porc, lapin, volailles. INRA 1989, Feedstuffs ingredient analysis table, edition 1996, AEC Table and 1995 UCAAB data.

**Table 16b: Significant differences in amino acid profiles between treated genetically modified hybrids and non-genetically modified hybrids.**

<sup>1</sup>

<b>Hybrid</b>	<b>Proline (mg/kg)</b>		<b>Alanine (mg/kg)</b>	
	<b>Bt11 hybrid<sup>2</sup></b>	<b>Control hybrid</b>	<b>Bt11 hybrid<sup>2</sup></b>	<b>Control hybrid</b>
Madera	5640	7730	4720	5330
Manuel	7520	9210	5520	5730
Magister	7740	8830	4930	5440

<sup>1</sup>Values are all expressed as mg/kg.

(iii) *Fatty acid analysis*

Fatty acid levels were also analysed. No significant differences were found between fatty acid values for treated and untreated genetically modified corn plants and also between the untreated modified plant and control lines (P=5%) (Table 17).

**Table 17: Fatty acid analyses for treated Bt-11 plants and control corn plants<sup>1</sup>.**

	<b>Treated</b>	<b>Untreated</b>	<b>Control</b>
Palmitic	12.4 ± 1.9	12.3 ± 1.2	11.2 ± 1.2
Stearic	2.3 ± 0.2	2.4 ± 0.3	2.2 ± 0.2
Oleic	28.0 ± 1.9	27.4 ± 2.0	27.2 ± 1.3
Linoleic	55.1 ± 2.7	55.8 ± 3.0	57.0 ± 2.3
Linolenic	1.1 ± 0.2	1.1 ± 0.2	1.2 ± 0.2

<sup>1</sup>Values expressed as a % of total fatty acids. Values are means of 3 samples, one from each of the hybrids Madera, Manuel and Magister.

## **5.2 Levels of anti-nutrients**

Corn contains few natural toxins or anti-nutrients. The anti-nutrients trypsin and chymotrypsin inhibitors are present in corn at very low levels and are not considered nutritionally significant (Wright 1987).

## **5.3 Ability to support typical growth and well-being**

In assessing the safety of a genetically modified food, a key factor is the need to establish that the food is nutritionally adequate and will support typical growth and well-being. In most cases, this can be achieved through an understanding of the genetic modification and its consequences, together with an extensive compositional analysis of the food. Where, on the basis of available data, there is still concern or doubt in this regard, carefully designed feeding studies in animals may provide further reassurance that the food is nutritionally adequate. Such studies may be considered necessary where the compositional analysis indicates significant differences in a number of important components or nutrients or where there is concern that the bioavailability of key nutrients may be compromised by the nature of the genetic changes to the food.

The compositional and other data presented in the application are considered adequate for establishing the nutritional adequacy of Bt-11 corn. Additional studies, including animal feeding studies are therefore not required.

## **5.4 Conclusions regarding nutritional issues**

The nutritional qualities of insect-protected Bt-11 corn were determined by compositional analyses of the major components of the kernels and these were found to be comparable in all respects to the conventional corn lines.

There is a long history of safe use of corn. Based on the data submitted in the present application, grain derived from Bt-11 corn is nutritionally and compositionally comparable to that from conventional corn and is not considered to pose a risk to human health and safety.

## **Acknowledgements**

ANZFA gratefully acknowledges Dr Brian Jordan, Associate Professor, Director, Nutrition and Health, Institute of Food Nutrition and Human Health, Massey University, New Zealand, for expert comments on this safety assessment report.

## References

- Alexander, R.J. 1987 Corn dry milling: processes, products and applications. *in* Corn: Chemistry and Technology. ed. Watson, S.A. and Ramstead, P.E. American Association of Cereal Chemists Inc, St Paul, Minnesota. pp 351-376
- ANZFA 1999. Guidelines for the safety assessment of foods to be included in Standard A18 — Food Produced Using Gene Technology.
- Calva JJ, Sifuentes-Osbornio J and Ceron C 1996. Antimicrobial resistance in fecal flora: longitudinal community-based surveillance of children from urban Mexico. *Antimicrobial Agents and Chemotherapy* 40:1699-1701.
- Frick, O.L. 1995 The potential for allergenicity in transgenic foods. *in* *Genetically Modified Foods: Safety Aspects*. K.-H. Engel, G.R. Takeoka and R. Teranishi. (eds) American Chemical Society, Washington DC.
- Geiser, M., Schweitzer, S. and Grimm, C. 1986 The hypervariable region in the genes encoding entomopathogenic crystal proteins of *Bacillus thuringiensis*: nucleotide sequence of the kurhd1 gene of subsp. *kustaki* HD1. *Gene* 48: 109-118
- Hammond BG and Fuchs RL 1998. Safety evaluation for new varieties of food crops developed through biotechnology. In: Thomas JA (ed.) *Biotechnology and safety assessment*. Taylor and Francis, Philadelphia.
- Hofte, H. and Whitely, H.R. 1989 Insecticidal crystal proteins of *Bacillus thuringiensis*. *Microbiol Rev* 53: 242-255.
- INRA. 1989. L'alimentation des animaux monogastriques: porc, lapin, volailles. Feedstuffs ingredient analysis table, edition 1996, AEC Table and 1995 UCAAB data
- Jones DD and Maryanski JH 1991. Safety considerations in the evaluation of transgenic plants for human food. In: Levin MA and Strauss HS (eds) *Risk assessment in genetic engineering*. New York: McGraw-Hill.
- Kues U and Stahl U 1989. Replication of plasmids in gram-negative bacteria. *Microbiological Reviews* 53:491-516.
- Lehrer, S.B., W.E. Horner and Reese, G. 1996. Why are some proteins allergenic? Implications for biotechnology. *Crit Rev Food Sci Nutr* 36: 553-564.
- Lehrer SB and Reese G 1998. Food allergens: implications for biotechnology. In: Thomas JA (ed.) *Biotechnology and safety assessment*. Taylor and Francis, Philadelphia.
- Mascarenhas D, IJ Mettler, DA Pierce and HW Lowe. 1990. Intron-mediated enhancement of heterologous gene expression in maize. *Plant Mol. Biol.* 15:913-920
- May, J.B. 1987 Wet milling: processes and products. *in* Corn: Chemistry and Technology. ed. Watson, S.A. and Ramstead, P.E. American Association of Cereal Chemists Inc, St Paul, Minnesota. pp 377-397
- Negrutiu I, R Shillito, I Potryjus, G Biasini and G Sala. 1987. Hybrid genes in the analysis of transformation conditions. *Plant Molec. Biol.* 8:363-373.
- Noteborn HP, Bienenmann-Ploum ME, van den Berg JH, Alink GM, Zolla L, Reynaerts A, Pensa M and Kuiper HA 1995. Safety assessment of the *Bacillus thuringiensis* insecticidal crystal protein Cry1A(b) expressed in transgenic tomatoes. In: *Genetically modified foods*. American Chemical Society Symposium Series 605. Engel K-H, Takeoka GR and Teranishi R (eds) American Chemical Society, Washington, DC.
- Perlak, F.J., Fuchs, R.L., Dean, D.A., McPherson, S.L., Fischhoff, D.A. 1991 Modification of the coding sequence enhances plant expression of insect control protein genes. *Proc Natl Acad Sci USA* 88: 3324-3328
- Rogers, J. 1990 What food is that? and how healthy is it? Weldon Publishing, Sydney p 326-327

- Sanders PR, Lee TC, Groth ME, Astwood JD and Fuchs RL 1998. Safety assessment of insect-protected corn. In: Thomas JA (ed.) *Biotechnology and safety assessment*. Taylor and Francis, Philadelphia.
- Schnepf, E., Crickmore, N., Van Rie, J., Lereclus, D., Baum, J., Feitelson, J., Zeigler, D.R. and Dean, D.H. 1998 *Bacillus thuringiensis* and its pesticidal crystal proteins. *Microbiol Mol Biol Rev* 62: 775-806
- Stewart GJ and Carlson CA 1986. The biology of natural transformation. *Annual Review of Microbiology*, 40:211-235.
- Strauch E., Wohlleben, W. and A. Puhler. 1988. Cloning of a phosphinothricin N-acetyl transferase gene from *Streptomyces viridochromogenes* Tü4994 and its expression in *Streptomyces lividans* and *Escherichia coli*. *Gene* 63:65-77
- Taylor S.L. and S.B. Lehrer. 1996. Principles and characteristics of food allergens. *Crit Rev Food Sci Nutr* 36 Suppl: S91-S118.
- Thompson, C.K., Rao Movva, N., Tizard, R., Crameri, R., Davies, J.E., Lauwereys, M. and Botterman, J. 1987 Characterization of the herbicide resistance gene *bar* from *Streptomyces hygroscopicus*. *EMBO J* 6: 2519-2623
- Weber, E.J. 1987 Lipids of the kernel. *in* *Corn: Chemistry and Technology*. ed. Watson, S.A. and Ramstead, P.E. American Association of Cereal Chemists Inc, St Paul, Minnesota. pp 311-349
- Wehrmann, A., A. Van Vliet, C. Opsomer, J. Botterman and A. Schulz. 1996. The similarities of *bar* and *pat* gene products make them equally applicable for plant engineers. *Nature Biotechnology* 14:1274-1278
- WHO 1991 Strategies for assessing the safety of foods produced by biotechnology. Report of a joint FAO/WHO Consultation. World Health Organization, Geneva, 59 pp.
- WHO 1993 Health aspects of marker genes in genetically modified plants. Report of a WHO Workshop. World Health Organization, Geneva, 32 pp.
- Wohlleben, W., Arnold, I. Broer, D. Hilleman, E. Strauch and. 1988. Nucleotide sequence of the phosphinothricin-N-acetyltransferase gene from a *Streptomyces viridochromogenes* T494 and its expression in *Nicotiana tabacum*. *Gene* 70:25-37.
- Wright, K.N. 1987 Nutritional properties and feeding value of corn and its by-products. *in* *Corn: Chemistry and Technology*. ed. Watson, S.A. and Ramstead, P.E. American Association of Cereal Chemists Inc, St Paul, Minnesota. pp 447-478

## DRAFT REGULATORY IMPACT ASSESSMENT

The Authority is required, in the course of developing regulations suitable for adoption in Australia and New Zealand, to consider the impact of various options (including non-regulatory options) on all sectors of the community, including consumers, the food industry and governments in both countries. The regulatory impact assessment will identify and evaluate, though not be limited to, the costs and benefits of the regulation, and its health, economic and social impacts.

### Identification of affected parties

1. Governments in Australia and New Zealand
2. Consumers in Australia and New Zealand
3. Manufacturers, producers and importers of food products

### Options

*Option 1—To prohibit the sale of food produced using gene technology*

<p><b>GOVERNMENT</b> Commonwealth, New Zealand Health Departments, State/Territory Health Departments</p>	<p><b>Benefits</b></p> <ul style="list-style-type: none"> <li>• no benefits were identified.</li> </ul>	<p><b>Costs</b></p> <ul style="list-style-type: none"> <li>• the governments of Australia and New Zealand may be challenged under the WTO to justify the need for more stringent restrictions than apply internationally.</li> <li>• a prohibition on food produced using gene technology in Australia and New Zealand could result in retaliatory trade measures from other countries.</li> <li>• there may be technical problems for AQIS in enforcing such a prohibition at the import barrier.</li> </ul>
<p><b>INDUSTRY</b> Manufacturers, producers and importers of food products</p>	<p><b>Benefits</b></p> <ul style="list-style-type: none"> <li>• Some companies may benefit from being able to exploit niche markets for non-GM products overseas.</li> </ul>	<p><b>Costs</b></p> <ul style="list-style-type: none"> <li>• food manufacturers and producers will be unable to use the processed food fractions from foods produced using gene technology thus requiring the switch to non-GM ingredients and the reformulation of many processed food products. The cost to manufacturers of going non-GM has been estimated to be \$A 207m in Australia and \$NZ 37m in New Zealand<sup>5</sup>. This is equivalent to 0.51% of turnover in Australia and 0.19% in New Zealand.</li> </ul>

<sup>5</sup> Report on the costs of labelling genetically modified foods (2000)

<b>CONSUMERS</b>	<b>Benefits</b> <ul style="list-style-type: none"> <li>• no benefits were identified, however as some consumers perceive GM food to be unsafe, they may perceive prohibition of GM food to provide a public health and safety benefit.</li> </ul>	<b>Costs</b> <ul style="list-style-type: none"> <li>• could lead to decreased availability of certain food products.</li> <li>• increased costs to consumers because manufacturers and producers may have to source non-GM ingredients.</li> </ul>
------------------	---	--

*Option 2– to permit the sale of food produced using gene technology*

<b>GOVERNMENT</b> Commonwealth, New Zealand Health Departments, State/Territory Health Departments	<b>Benefits</b> <ul style="list-style-type: none"> <li>• increased innovation and competitiveness in the food industry will benefit the economy.</li> </ul>	<b>Costs</b> <ul style="list-style-type: none"> <li>• minor costs associated with amending the <i>Food Standards Code</i>.</li> </ul>
<b>INDUSTRY</b> Manufacturers, producers and importers of food products	<b>Benefits</b> <ul style="list-style-type: none"> <li>• food producers and manufacturers will be able to capitalise on the latest technology.</li> <li>• food importers will continue to be able to import manufactured products from overseas markets including the USA and Canada where there is no restriction on the use of food produced using gene technology.</li> </ul>	<b>Costs</b> <ul style="list-style-type: none"> <li>• there may be some discrimination against Australian and New Zealand food products in overseas markets that have a preference for non-GM foods (e.g., Japan and the European Union).</li> </ul>
<b>CONSUMERS</b>	<b>Benefits</b> <ul style="list-style-type: none"> <li>• consumers may have access to a greater range of food products.</li> </ul>	<b>Costs</b> <ul style="list-style-type: none"> <li>• those consumers who wish to avoid GM food may experience restricted choice in food products.</li> <li>• those consumers who wish to avoid GM food may have to pay more for non-GM food.</li> </ul>

**Conclusion of the regulatory impact assessment**

Consideration of the regulatory impact for foods produced using gene technology concludes that the benefits of permitting foods produced using gene technology primarily accrue to the government and the food industry, with potentially a small benefit to consumers. These benefits are considered to outweigh the costs to government, consumers and industry, provided the safety assessment does not identify any public health and safety concerns.

## WORLD TRADE ORGANISATION AGREEMENTS

With the completion of the Uruguay Round of trade negotiations, the World Trade Organization (WTO) was created on 1 January 1995 to provide a forum for facilitating international trade.

The WTO does not engage in any standard-setting activities but is concerned with ensuring that standards and procedures for assessment of and conformity with standards do not create unnecessary obstacles to international trade.

Two agreements which comprise part of the WTO treaty are particularly important for trade in food. They are the;

- Agreement on the Application of Sanitary and Phytosanitary Measures (SPS); and
- Agreement on Technical Barriers to Trade (TBT).

These agreements strongly encourage the use, where appropriate, of international standards, guidelines and recommendations, such as those established by Codex (in relation to composition, labelling, food additives, veterinary drug and pesticide residues, contaminants, methods of analysis and sampling) and the code and guidelines on hygienic practice.

Both Australia and New Zealand are members of the World Trade Organization (WTO) and signatories to the agreements on the Application of Sanitary and Phytosanitary Measures (SPS agreement) and on Technical Barriers to Trade (TBT agreement). Within Australia, the Council of Australian Governments (COAG) has put in place a Memorandum of Understanding binding all States and Territories to the agreements.

The WTO agreements are predicated on a set of underlying principles that standards and other regulatory measures should be:

- based on sound scientific principles;
- developed using consistent risk assessment practices;
- transparent;
- no more trade-restrictive than necessary to achieve a legitimate objective;
- recognise the equivalence of similar measures in other countries; and
- not used as arbitrary barriers to trade.

As members of the WTO both Australia and New Zealand have an obligation to notify the WTO of changes to food standards to enable other member countries of the WTO to make comment. Notification is required in the case of any new or changed standards which may have a significant trade effect and which depart from the relevant international standard (or where no international standard exists). Matters raised in this proposal may be notified to the WTO as either SPS notifications or TBT notifications, or both.

## **SPS Notifications**

These are primarily health related, and refer to any sanitary and phyto sanitary measure applied:

- to protect animal or plant life from risks arising from the entry, establishment or spread of pests, diseases or disease carrying organisms;
- to protect human or animal life or health from risks arising from additives, contaminants, toxins or disease-carrying organisms in foods, beverages or foodstuffs;
- to protect human life or health from risks arising from diseases carried by animals, plants or products thereof, or from the entry, establishment or spread of pests; and
- to prevent or limit other damage from the entry, establishment or spread of pests.

The Agreement on the Application of Sanitary or Phytosanitary Measures relates to any sanitary or phytosanitary measure applied to protect animal, plant or human life or health which may directly or indirectly affect international trade. Whether the SPS measure is in the form of a law or mandatory regulation, an advisory guideline, a code of practice or a requirement, it is the purpose of the measure that is important - not its regulatory status. Each WTO member country is entitled to apply SPS measures that are more stringent than the international standards in order to protect the health of its population. In the interests of transparency, each instance of such non-alignment which could result in an impediment to trade must be identified and justified and the documentation of that justification must be readily available

Each member country is also required to apply its methods of risk assessment and management consistently so arrangements under the SPS Agreement do not generate what may really be technical barriers to trade

Under the SPS Agreement, an exporting country can have resort to the WTO's dispute settlement procedures with respect to such a non-alignment. These arrangements mean there is potential for a code of practice to introduce an SPS measure that may bring about non-alignment with international requirements. Such non-alignment would need to be justified scientifically on the grounds that it is necessary to protect human, animal or plant life or health.

## **TBT Notifications**

A technical barrier to trade arises when a mandatory requirement in a country's food regulatory system does not align with the international standard and it is more trade restrictive than is necessary to fulfil a legitimate objective. However, it can be acceptable for a country to have a more stringent requirement than that set internationally for reasons including:

- Maintaining national security;
- Preventing deceptive practices; and
- Protecting human health or safety.

Instances of non-alignment with international standards which could result in trade barriers must be identified and, if questioned, justified. Voluntary codes of practice are not expected to generate technical barriers to trade except where compliance with a code of practice or some aspect of a code of practice is expected. Consequently, it is possible for a voluntary code of practice to be viewed by the WTO as mandatory and subject to all the notification and other provisions applying to mandatory regulations.

The Agreement on Technical Barrier to Trade relates to requirements covering product characteristics or their related processes and production methods. TBT covers measures that are not SPS, such as requirements relating to terminology, symbols, packaging, marking, labelling, food composition and processing methods.

## SUMMARY OF PUBLIC COMMENTS

### National Genetic Awareness Alliance (Aus)

- Believes that the patenting of life-forms and living processes represents a violation of human rights, threat to food security, impediment to medical research and a threat to animal welfare
- Believes that current GM techniques are inherently hazardous, and have been shown recently to offer no benefits
  - Lower yields with high pesticide input
  - Intensification of the corporate monopoly on food
  - Spread of antibiotic resistance marker genes and promoter sequences
  - Possible increase of allergenicity due to spread of transgenic pollen
- Urges governments to use precautionary principle and carry out research into sustainable agricultural methods
- Calls for suspension of trials and sale of GM products and public inquiry.

### Pola Lekstan and Anna Clements (Aus)

- Are concerned that approval without long-term testing may pose a health threat, that more GM food means less choice for those wanting to avoid it, that Bt may affect non-target organisms, and that herbicide resistance may lead to overuse of chemicals.

### Arnold Ward (Aus)

- Questions the system of MRL setting in light of the levels of high glyphosate residues in Roundup Ready soybeans and of other chemicals (including the Bt toxin) in GM crops
- Is concerned about detrimental effect of Bt on non-target (beneficial) organisms and on humans, and believes that genetic engineering is imprecise with uncertainties in outcomes
- Believes that the concept of substantial equivalence is inadequate and should not be used to avoid more rigorous testing, and that commercial factors are overriding need for basic research. Also believes that ANZFA's arguments defend the needs of biotechnology companies and food processing industry, and that since ANZFA does no testing itself, the results can't be trusted.

### Australian GeneEthics Network

- Believes that the data provided is insufficient to make an assessment, and clock should be stopped on the applications. Concerns include:
  - Direct health effects of pesticide residues
  - Possibility of transfer of antibiotic resistance marker genes leading to resistant bacteria

- The possibility that transfer of other traits e.g. herbicide tolerance to bacteria, could lead to horizontal spread of unfavourable traits
- Insertion of viral DNA could create new and virulent viruses
- The possibility that approval could lead to the growing of GMOs in Australia – ecological concerns including effects of, and increases in resistance to, Bt-toxins and the encouragement of increased herbicide use resulting from herbicide-tolerant crops
- The threat to GE-free status export markets
- Believes that the term ‘substantial equivalence’ is not useful– compositional data alone does not establish equivalence

### **Public and Environmental Health Service (Aus)**

- Believes that the data provided should cover both the intentional and unintentional effects of the genetic modification. The unintended consequences of random insertion of new genetic material into the host genome could include loss or change of function of gene or controlling element, dysregulation or amended regulation of the gene or controlling element, or production of a novel hybrid protein which could occur in an unregulated manner. They should also cover any compositional changes e.g. nutrients, antinutritional factors, natural toxicants, and define when a change would be considered ‘significant’
- Potential effect of introduced proteins on metabolic pathways should be addressed e.g. over-expression or inhibition of enzymes
- Data should include details of whether introduced proteins are detectable in whole commodities, processed products and highly processed derivatives
- Data should include details of toxicity and allergenicity tests to prove that food is safe, as well as address issues of specificity and potency of proteins. It should also address the ability to support typical growth and well-being
- Data for herbicide-tolerant plants should be derived from studies performed on plants treated with herbicide. They should address the human toxicity of the herbicide and whether residues of the herbicide degradation process are present, toxic and/or subject to an MRL.

### **David Grundy (Aus)**

- Considers that the expression of Bt toxins and other chemicals in plant tissues removes the choice of washing chemicals off fruit and vegetables. Believes that Roundup Ready crops have glyphosate or glufosinate molecules genetically attached
- Believes that GM crops should not be used for feed given to animals bound for human consumption, that products encouraging antibiotic resistance should not be used, and that labelling should be mandatory for all products containing GM ingredients

### **Leesa Daniels (Aus) Member of the Genetic Engineering Action Group**

- Believes that:
  - Scientific research although limited, has brought concerns to light
  - Substantial equivalence is a subjective principal

- Comprehensive and mandatory labelling must be urgently implemented
- The Cauliflower Mosaic Virus (CaMV) promoter could enhance the capability to transfer genes horizontally and has the potential for activating dormant or new viruses
- Antibiotic marker genes could lead to increase in antibiotic resistance
- Several of the transformations encourage the use of pesticides, all of which have shown to be harmful.

### **Australian Food and Grocery Council**

- Fully endorses the policy of minimum affective regulation, supports these applications, and considers that food manufacturers should make their own choice with regard to use of GM crops or products derived from them
- Believes that since the growth of GM crops has been approved overseas, they would support their growth in Australia if approved through the GTAC/GMAC/OGTR process
- Considers it unfortunate that ANZFA has not negotiated “equivalence” agreements for products already approved overseas to enable approval without having to carry out its own safety assessment. In the absence of such an agreement it supports the ANZFA safety assessment process.
- Believes that an appropriate information and labelling scheme would enable consumers to make an informed choice.

### **New Zealand Ministry of Health**

- Referred preliminary report to New Zealand Health Research Council, who stated concern that all safety aspects should be carefully considered in the ANZFA process.

### **Nestle Australia Ltd.**

- Supports the continued approval of glufosinate ammonium-tolerant canola, and believes that manufacturers would be disadvantaged were approval not to be granted.

### **Consumers’ Association of South Australia Inc. & National Council of Women of Australia (CASA supports submission of NCWA)**

- Believe that current testing procedure is inadequate and that human trials are the only adequate method, as with testing of new drugs. Also that physiological and neurological effects as well as the toxicological and allergenic effects should be looked at, and that an independent body should be responsible for testing.
- Do not support the use of antibiotic markers, since they believe they may pose a threat to efficacy of antibiotics in humans.
- State that new research has shown that GM soybeans may be a less potent source of phytoestrogens than conventional soybeans confirming the inadequacy of the term ‘substantial equivalence’.
- Raise the point that although these crops have been approved elsewhere, this situation may change with consumer pressure.

- Do not accept that it is impossible to source food to ascertain whether or not it contains GM ingredients. Believe that if McCain and Sanitarium can do it, then others should also be able to.
- State general concern about the risk that MRLs will be raised as a result of herbicide-tolerant crops being developed, and feel that the calculations used are flawed and are not based on safety criteria.
- Believe that the use of GM crops in animal feed should also be regulated. A378
- State concern over possible increase in glyphosate use (it is apparently confirmed in one reference that herbicide use increases with herbicide resistant crops), referring to studies that link the chemical to Hodgkin's lymphoma, and the possibility that Europe may ban it due to adverse effects on beneficial insects. They are particularly concerned that glyphosate is not looked at by the same regulatory body as that looking at GM foods.

#### **A379, A38**

- State concern over the persistence and toxicity of bromoxynil, and consider that these have not been adequately assessed by the US FDA. They understand that the breakdown product of bromoxynil (DBHA) may be more potent than bromoxynil itself, and believe that a safety assessment needs to be done on this too. This is apparently the main residue, and they believe that this may appear in cotton oil and linters.

#### **A372, A375, A380, A381, A386**

- With respect to glufosinate ammonium, state concern about toxicity, neurotoxicity, teratogenicity and residues in food, soil and water. They believe that Monsanto is likely to apply for an increase in the MRL, and that such increases are likely to constitute a health hazard.

#### **A380, A382, A383, A384, A385, A386**

- Raise issues of adverse effects of Bt toxins on non-target insects and think that it needs more study.

#### **A387**

- Believe that raising the amount of a nutrient in a food may have unknown drawbacks e.g. affecting the efficacy of other nutrients.

### **Health Department of Western Australia**

- Highlights various health and environmental concerns:
  - the use of antibiotic resistance genes as markers may transfer resistance to animals via gut bacteria
  - the possibility that microbial gene sequences may contain fragments of other virulent genes, and also that ingesting Bt toxins may be harmful to humans
  - the possibility that insects may be more prone to developing resistance to Bt, since Bt toxins have been found to be released into the soil
- Believes that both safety data and gene sequences should be available for public scrutiny

## **Meat New Zealand**

### **A379**

- Concerned at how labelling regulations will apply to sausage casings that may contain cotton linters even if they are not to be eaten, i.e. are effectively a processing aid. Think that labelling should only be used to advise the sausage manufacturer not consumers.

## **BRI Australia**

- Supports the approval of all 13 applications provided ANZFA is satisfied with their safety.

## **Food Technology Association of Victoria Inc.**

- Supports the approval of all 13 applications provided ANZFA is satisfied with their safety.

## **Diane Davie (Aus)**

- Believes all 13 applications should be rejected, since they have not undergone human safety testing here or overseas, and have not been assessed on their ethical merits
- Believes that risks include:
  - Bacterial and viral vectors which could affect human physiology
  - Herbicide and insect-resistance genes, which could increase allergies and antibiotic resistance
  - Environmental risks
- Also believes that ANZFA must heed the concerns of consumers opposed to GM foods.

**Martin Hurley, David Hook, Ian Smillie, Margaret Dawson, Tee Rodgers-Hayden, David Lovell-Smith (Natural Law Party), Barbara Brown, Ngaire Mason, Robert Anderson (member, Physicians and Scientists for Responsible Genetics), Louise Carroll, Gilbert Urquart, Caroline Allinson-Dunn, Megan Lewis, Peter Barnes, James Harlow, Gabrielle Dewan, Scott Young, Virginia Murray, Stephanie Chambers, Kay Dyson, Peter Fenwick, Joanne Xerri, Paul True, Josh Gill, James & Peysha Charlwood, Mitta Hirsch, Alan Florence, Nicole Paul, Lawrence Clarke, David Snowman, Reg Paling, Mark and Johanna Blows, David and Bev Semour, Richard and Sharon Moreham (see also below), Stuart Drury and Helen Murphy (All Aus), Brennan Henderson (NZ) – Generic e-mail objection.**

- Believe that most Australians and New Zealanders do not want GM foods, there are no benefits, and deferral would not be disadvantageous. Approval should be delayed until they are proven safe.

- Feel that there is insufficient time to assess these applications thoroughly, and there are so many products under development that there is a high overall risk of a major disaster
- Believe that GM foods encourage pesticide use, and applications have made for commercial purposes only, and also that there could be commercial benefit to Australia and New Zealand in remaining GM-free.

**Richard and Sharon Moreham (see also above)**

- In addition to the points above, also think that it is unfortunate that the NZ government agreed to joint approval of food, as the Australian public are less educated about the issues surrounding GM foods
- Think that approval would only prove that ANZFA serves the interests of large multinational companies rather than those of the public.

**Vicky Solah (Aus)**

- Is for GM foods if the safety evaluation is carry out using approved, validated methods by an independent body, if the results are made available to consumers, and if all GM food is labelled
- Is concerned that transformation may lead to disruption of another gene, and that more research is needed before it is clear whether the process is safe
- With regard to herbicide tolerant crops, is concerned that consumers may not be aware of the need to wash products that have been sprayed, and that this therefore impacts on food safety. Also concerned about environmental impact of these chemicals, and of the possibility of resistance necessitating higher pesticide use in the future.

**Dr Rosemary Keighley (Aus)**

- Will not purchase foods unless they are certified GM-free. Believes that Australian producers who do not actually use GM products, but who fail to label them as such, will suffer.

**Nicola Roil (Aus)**

- Believes that GM foods pose health threats and may contaminate non-modified crops.

**Ian and Fran Fergusson (Aus) – also in generic email above**

- Believe there has been inadequate testing, and are concerned about possible side-effects.

**Lyndal Vincent (Aus)**

- Urges delay of approval until proven safe by extensive testing. Considers that genetic material is being released without knowing what the effects are, and cannot be recalled.
- Believes that there is no benefit to the consumer, and that national economic interests are best served by maintaining a GM-free market.

**Fay Andary (Aus)**

- Does not want any of the 13 products covered by the applications to be approved for inclusion in the food supply.

**John and Francesca Irving (Aus)**

- Thinks that no GE foods should be approved for inclusion in the food chain.

**Diana Killen (Aus)**

- Believes that there is no proven benefit to consumers and in many instances nutritional value is actually lower in GM crops, and it is therefore irresponsible to push through approval without thorough assessment of their long-term safety for public health.
- Suggests that research has highlighted adverse allergic reactions and a lowered immune response in some individuals, and that there are health implications with crops designed to be grown with greater concentrations of pesticides.
- Thinks that labelling is essential for consumers to discriminate in purchasing, and that Australia has a unique opportunity in supply of organic and GM-free food.

**Sheila Annesley (Aus)**

- Does not want any of the 13 foods included in the food supply.

**David and Edwina Ross (Aus)**

- State concern for the future food supplies and well-being of their grandchildren.

**Beth Schurr (Aus)**

- Wishes to protest against the threat of GM foods, the possible future detrimental effects and the further endangering of the planet.

**Beth Eager (Aus)**

- As a parent is concerned that neither the long-term effects on health nor the environment are being considered.

### **Bruce Pont and Ljiljana Kuzic-Pont (Aus)**

- Believe that safety has not been, and cannot be satisfactorily determined, and that any party associated with GM foods could be legally liable should adverse health effects be seen. Thalidomide, smoking, 'Agent Orange' and asbestos all show that such things can affect subsequent generations
- Believe that an increase in use of pesticides will result from pesticide-tolerant crops, and that the emphasis should be on organic and/or safe agriculture
- Believe that GM-food is a retrograde step, contrary to nature and has the potential to destroy the human race.

### **Chitta Mylvaganum (Aus)**

- Wishes to know what tests were done to assess negative effects on human and environmental health, how thorough they were, what the outcomes were, are the results publicly available, and what further avenues of inquiry are open to the public
- Requests the prevention of the import or release of any products until tests are carried out by unbiased scientists in order to prove the lack of health or environmental effects.

### **John Stevens (Aus)**

- Would be concerned if approval were granted before sufficient research had been completed on potential impacts on human health and gene pools of nearby crops. Once grown, spread via pollen would be impossible to stop, and labelling would not prevent exposure by this route.
- Considers that utmost caution should be exercised and import approval denied indefinitely.

### **Tim Carr (Convenor of the Emergency Committee against GE Foods)**

- Believes that GM-foods are produced using a radical and unpredictable new technology so should be subject to more rigorous testing.
- States that it is unknown how the introduced gene will interact with and influence genetic expression in the host genome, and could change the chemical nature of the food.
- Considers that health risks could result from the increased use of pesticides, and also that ANZFA should consider wider environmental, ethical and socio-economic issues.

### **Jan Kingsbury (Aus)**

- Believes that GM-foods could result in loss of economic advantage for Australia and New Zealand since they are known internationally for pure and safe products.
- Believes that foods are being complicated and pushed by big internationals, and organic farmers are being contaminated by cross-pollination.

### **Teresa Sackett (Aus)**

- Believes that:
  - The KPMG report on labelling was prepared in a ridiculously short time and provided limited analysis
  - The proposal of ‘no label’ for foods which ‘may contain’ or in which there is ‘no evidence’ of GM material is inadequate
  - Inadequate testing procedures should not be used to declare a product is GM-free just because material can’t be detected. In fact testing methods have been developed that can be used to work out the GM content
  - Government and industry seem to be favouring the introduction of GM foods. This will result in:
    - Increased use of chemicals
    - Destruction of soil life
    - Organic farming pay high costs for producing healthy plants, while conventional farmers have little restriction on pollution of air, soil and water. Salinity problems, the death of the Great Barrier Reef, rivers and streams has resulted from ignorance in farming and broader community. Such problems will increase with GM foods.
  - The implication that the public will not understand the issues is wrong. Everyone needs to be fully informed.
- Asks the question of whether workers in the food industry are to be better informed, and also why no ‘verification documents’ are to be required by retailers? Believes that certification schemes should be on a par with those for Kosher foods and organics.

### **John and Sandy Price (Aus)**

- Approval of GM foods and seeds should not be allowed, as it is an affront to the sovereignty of Australia and the dignity of the Australian people. The results of the experiment cannot be reversed.

### **John Scott (NZ)**

- Encloses article from The Irish Times, which describes the restrictions that have been placed by the US EPA on the cultivation of GM corn. These appear to have resulted from fears that Bt crops may be harmful to Monarch butterflies and that resistance may develop to Bt.

### **R A Randell (NZ)**

- Believes that all GM products should be placed under a moratorium until the Royal Commission of Inquiry has considered the issue, and until all scientific, philosophical, ethical and moral issues have been looked at.

## **National Council of Women of New Zealand**

- Believes that:
  - approval of all 13 applications should be rejected, and that none should be approved for planting.
  - Independently-funded body should be responsible for safety assessments
  - If it is possible to segregate high-oleic soybeans, then RoundUp Ready soybeans should be segregated too
  - Consumers should be made aware of the extent of GM ingredients in their food
  - GM foods, additives or processing aids already on the market must be labelled comprehensively and without extra cost to the consumer – suggest ‘GM unknown’ rather than ‘may contain’
- Appreciates that rejection may contravene the WHO agreement, but consider that the primary role of ANZFA is the assurance of health and safety.

## **Safe Food Campaign (NZ)**

- Believes that approval should be rejected, and a moratorium be put in place until after the Royal Commission of Inquiry, for various reasons:
  - Possible effects on non-target insects
  - Spread of GM pollen may cause contamination of non-GM (especially organic) crops, and may result in the spread of herbicide-tolerance genes and an increase in resistance development. Cross-pollination is considered a particular risk for canola (A372 & A388). Bt resistance development is noted as being a particular risk for A382, A383 & A384
  - Lack of long-term testing means health risks are not known
  - Use of broad-spectrum pesticides affects wild flowers and non-target insects.

## **Jocelyn Logan, Caroline Phillips (NZ)**

- Oppose all 13 applications for the following reasons:
  - Testing has not been long-term or independent, precautionary principle should apply. Approval can happen later if GM is proven safe.
  - No clear public benefit, and lack of opportunity for informed choice (immoral and undemocratic). Labelling regulations also unsatisfactory in this respect.
  - Environmental concerns (increase in pesticides, threat to organic farming, Bt resistance)

## **Robert Anderson (member of Physicians and Scientists for Responsible Genetics - NZ)**

- Considers that the GM issue should be reconsidered in the light of the release of internal FDA documents made available for a recent lawsuit aimed at amending their policy. Attached document (presentation given by Steven Druker, Alliance for Bio-integrity) suggests that:
  - Scientist’s warnings have been ignored

- FDA policy may be illegal, violating the Food, Drugs and Cosmetic Act – Mr Druker believes that the term generally-regarded-as-safe (GRAS) cannot apply to foreign DNA

### **Stephen Blackheath (NZ)**

- Argues that ANZFA’s approach to safety assessments is scientifically unsound:
  - Antibiotic resistance marker genes have been cited as being potentially dangerous by groups other than ANZFA e.g. the Royal Society
  - Unanticipated toxins and allergens are a concern, and it is suggested that the ANZFA process does not adequately consider these possibilities
  - Doesn’t address the question of whether risks exist that are unique to the GM process
  - It relies on data from the manufacturers themselves, with little sway given to evidence from public submissions. Companies have vested interests the results and cannot be trusted (also gives evidence of Monsanto’s past dishonesty)
- Believes that ANZFA is subject to undue influence through the directors, and is biased towards being pro-GM
- Suggests that RoundUp Ready soybeans are not substantially equivalent as the stems have been found to be more brittle than traditional lines, and may be lower in phytoestrogen content
- Also cites the lawsuit being brought by the Alliance for Bio-integrity, and the internal FDA documents that suggest concern from FDA scientists, as evidence of the FDA ignoring important evidence.

### **Claire Bleakley (NZ)**

- Believes that approval should be rejected for various reasons:
  - They may be against Maori views
  - Further long-term trials are needed and should be carried out by ANZFA themselves - certain trials have apparently shown effects on immune system, allergies and rare syndromes
  - Health concerns of pesticide overuse
  - The possibility of horizontal gene transfer with respect to antibiotic resistance transfer
  - Lack of labelling and the use of the unsatisfactory ‘substantial equivalence’ concept, which makes hazard difficult to assess
  - There is no substantial gain to consumers.

## GENERAL ISSUES RAISED IN PUBLIC COMMENTS

The majority of submissions received in response to the Section 14 Gazette Notice, expressed general views against the use of gene technology, asserted that food produced using this technology is unsafe for human consumption and expressed opposition to the sale of the food, irrespective of the type of food concerned or the particular genetic modification. An evaluation of these general issues raised by the submissions appears below.

### 1. The safety of genetically modified foods for human consumption

A majority of submitters raised the issue of public health and safety in relation to food produced using gene technology. In particular, it was stated that there has been inadequate testing of genetically modified foods, that there is limited knowledge concerning the risks associated with the technology and that there may be potential long-term risks associated with the consumption of such foods.

#### *Evaluation*

It is a reasonable expectation of the community that foods offered for sale are safe and wholesome. In this context, 'safe' means that there is a reasonable certainty of no harm. As with other aspects of human activity, the absolute safety of food consumption cannot be guaranteed. Conventionally produced foods, while having a long history of safe use, are associated with human disease and carry a level of risk which must be balanced against the health benefits of a nutritious and varied diet.

Because the use of gene technology in food production is relatively new, and a long history of safe use of these foods has yet to be established, it is appropriate that a cautious approach is taken to the introduction of these foods onto the market. The purpose of the pre-market assessment of a food produced using gene technology under Standard A18 is to establish that the new food is at least as safe as existing foods. The comprehensive nature of the scientific safety assessment, undertaken on a case-by-case basis, for each new modification is reflective of this cautious approach.

The safety assessment focuses on the new gene product(s), including intentional and unintentional effects of the genetic modification, its properties including potential allergenicity, toxicity, compositional differences in the food and its history of use as a food or food product.

Foods produced using gene technology are assessed in part by a comparison with commonly consumed foods that are already regarded as safe. This concept has been adopted by both the World Health Organisation (WHO)/Food and Agriculture Organisation (FAO) and the Organisation for Economic Cooperation and Development (OECD). The Authority has developed detailed procedures for the safety assessment of foods produced using gene technology that are consistent with international protocols developed by these bodies.

## 2. The need for long-term feeding studies

A number of submissions were concerned about the lack of long-term toxicity studies on genetically modified foods.

### *Evaluation*

Animal studies are a major element in the safety assessment of many compounds, including pesticides, pharmaceuticals, industrial chemicals and food additives. In most cases, the test substance is well characterised, of known purity and of no nutritional value, and human exposure is generally low. It is therefore relatively straightforward to feed such compounds to animals at a range of doses (some several orders of magnitude above expected human exposure levels) in order to identify any potential adverse effects of importance to humans. Establishing a dose-response relationship is a pivotal step in toxicological testing. In this way it is possible, in most cases, to determine the levels of exposure at which adverse effects are not present and so establish safe upper limits through applying appropriate safety factors.

By contrast, foods are complex mixtures of compounds characterised by wide variations in composition and nutritional value. Due to their bulk, they can usually be fed to animals only at low multiples of the amounts that might be present in the human diet. Therefore, in most cases, it is not possible to conduct dose-response experiments for foods in the same way that these experiments are conducted for chemicals. In addition, a key factor to be considered in conducting animal studies on foods is the need to maintain the nutritional value and balance of the diet. A diet that is poorly balanced will compromise the interpretation of any feeding study, since the effects observed will confound and usually override any small adverse effect which may be related to a component or components of the food. Identifying any potentially adverse effects and relating these to an individual component or characteristic of a food can, therefore, be extremely difficult. Another consideration in determining the need for animal studies is whether it is appropriate from an ethical standpoint to subject experimental animals to such a study if it is unlikely to produce meaningful information.

If there is some reason to question the safety of a newly-expressed protein in a genetically-modified food, it is more appropriate to examine the safety of this protein alone in an animal study rather than when it is part of a whole food. For newly-expressed proteins in genetically-modified foods, the acute toxicity is normally examined in experimental animals. In some case, studies up to 14 days have also been performed. These can provide additional re-assurance that the proteins will have no adverse effects in humans. Such experiments can provide more meaningful information than similar experiments on the whole food. Additional re-assurance regarding the safety of newly-expressed protein can be obtained by considering the digestibility of the new protein in *in vitro* assays using conditions which simulate the human gastric system.

## 3. Substantial equivalence

A number of submitters expressed concern regarding the use of the concept of substantial equivalence. Some rejected the premise of substantial equivalence on the grounds that differences at the DNA level make foods substantially different.

## *Evaluation*

*Substantial equivalence* embodies the concept that, as part of the safety assessment of a genetically modified food, a comparison can be made in relation to the characteristics and properties of the new and traditionally-produced food. This can include phenotypic<sup>2</sup> characteristics and compositional factors, as well as the levels of naturally occurring allergens, toxins and anti-nutrients.

This allows the safety assessment to focus on any significant differences between the genetically modified food and its conventionally produced counterpart. Genotypic differences (i.e. differences at the DNA level) are not normally considered in a determination of substantial equivalence, if that difference does not significantly change the composition of the new food relative to the conventional food.

The concept of substantial equivalence allows for an evaluation of the important constituents of a new food in a systematic manner while recognizing that there is a general acceptance that normally consumed food produced by conventional methods is regarded by the community as safe. It is important to note that, although a genetically modified food may be found to be different in composition to the traditional food, this in itself does not necessarily mean that the food is unsafe or nutritionally inadequate. Each food needs to be evaluated on an individual basis with regard to the significance of any changes in relation to its composition or to its properties.

The concept of substantial equivalence was first espoused by a 1991 Joint Consultation of the Food and Agricultural Organisation (FAO) and the World Health Organisation (WHO) where it was noted that the '*comparison of a final product with one having an acceptable standard of safety provides an important element of safety assessment.*'

The concept has been internationally recognised and embraced as a valuable tool in the safety assessment of foods produced using gene technology. The OECD also advocates an approach to safety assessment based on substantial equivalence as being '*the most practical to address the safety of foods and food components derived through modern biotechnology.*'

#### **4. The nutritional value of food produced using gene technology**

A small number of submitters expressed concern that the genetic alteration of food decreases its nutritional value.

## *Evaluation*

The assessment of food produced using gene technology by ANZFA entails an exhaustive evaluation of technical data on any intentional or unintentional compositional changes to the food. This assessment encompasses the major constituents of the food (fat, protein, carbohydrate, fibre, ash and moisture) as well as the key nutrients (amino acids, vitamins, fatty acids). There is no evidence to suggest that genetic modification *per se* reduces the nutritional value of food.

In the future, it is proposed that genetic modification be used intentionally to improve the nutritional value of food. In this regard, GM foods may be able to assist in addressing the

---

<sup>2</sup> characteristics that are visible

general nutritional issues of the community and also specific dietary problems of sub-populations.

## **5. Potential toxins and allergens**

Some submitters expressed concerns about the risks of the introduction of new toxins or allergens.

### *Evaluation*

This issue is considered in detail as part of the safety assessment conducted on each new genetic modification applied to a food or commodity crop. New toxins or allergens may be introduced into food by either gene technology or by traditional breeding techniques, or by altered production processes. It is also possible to use these techniques to develop foods specifically where such compounds are significantly reduced or eliminated. One advantage of gene technology, in comparison with these other methods, is that any transferred genes are well characterised and defined, thus the possibility of developing a food with a new toxic or allergenic compound is likely to be reduced.

## **6. Antibiotic resistance**

Some submitters raised concerns about increased antibiotic resistance resulting from the use of gene technology. Some felt that it would be reassuring if independent biomedical advice were available to reassure the public that the use of antibiotic resistance markers does not pose a risk to the future use of antibiotics in the management of human disease.

### *Evaluation*

The human health considerations in relation to the potential for the development of antibiotic resistance depend on the nature of the novel genes and must be assessed on a case-by case basis. This issue arises because of the use of antibiotic resistance marker genes in the generation of genetically modified plants. In some circumstances, antibiotic resistance genes are linked to the gene of interest, to enable the initial selection of the engineered cells in the laboratory. Those cells that contain the antibiotic resistance marker gene, and hence the gene of interest, will be able to grow in the presence of the antibiotic. Those cells that failed the transformation process are eliminated during the selection procedure.

Concern has arisen that ingestion of food containing copies of antibiotic resistance genes could facilitate the transfer of the gene to bacteria inhabiting the gut of animals and humans. It is argued that these genes may then be transferred to disease causing bacteria and that this would compromise the therapeutic use of these antibiotics.

In 1993, the World Health Organisation Food Safety Unit considered this issue at a Workshop on the health aspects of marker genes in genetically modified plants. It was concluded at that Workshop that the potential for such gene transfers is effectively zero, given the complexity of the steps required. Since this time, several separate expert panels (Report to the Nordic Council, Copenhagen 1996; Advisory Committee on Novel Foods and Processes, UK 1994, 1996; The Royal Society, UK 1998) and numerous scientific papers published in peer reviewed journals have also considered the available evidence on this issue. It is generally agreed that the presence and subsequent transfer of an intact functional gene from transgenic

food to micro-organisms in the human intestine is an extremely unlikely event. Furthermore, if this were to occur, bacteria would not normally retain the resistance genes unless there was an environment for positive selection. The majority of these genes provide for resistance to antibiotics whose use is confined to the laboratory and are not considered to be of major therapeutic use in humans.

Antibiotic resistant bacteria are naturally occurring, ubiquitous and normally inhabit the gut of animals and humans. There is a general consensus that the transfer of antibiotic resistance genes is much more likely to arise from this source and from associated medical practices, rather than from ingested genetically modified food. Even so, at the recent OECD Conference (GM Food Safety: Facts, Uncertainties, and Assessment) held in Edinburgh on 28 February – 1 March 2000, there was general consensus that the continued use of antibiotic marker genes in GM food crops is unnecessary given the existence of adequate alternatives, and should be phased out.

## **7. Transfer of novel genes**

Some submitters have expressed concern that the transfer of any novel gene may be a health concern.

### *Evaluation*

It is extremely unlikely that novel genetic material will transfer from GM foods to bacteria in the human digestive tract because of the number of complex and unlikely steps that would need to take place consecutively. It is equally unlikely that novel genetic material will transfer from GM foods to human cells via the digestive tract. In considering the potential impact on human health, it is important to note that humans have always consumed large amounts of DNA as a normal component of food and there is no evidence that this consumption has had any adverse effect on human health. Furthermore, current scientific knowledge has not revealed any DNA sequences from ingested foods that have been incorporated into human DNA. Novel DNA sequences in GM foods comprise only a minute fraction of the total DNA in the food (generally less than 0.01%) and are therefore unlikely to pose any special additional risks compared with the large amount of DNA naturally present in all foods.

## **8. Viral recombination**

Some submitters expressed concern about the long term effects of transferring viral sequences to plants.

### *Evaluation*

This is an issue that is commonly raised because some of the genes that are transferred to plants use a plant virus promoter. Promoters are controlling DNA sequences which act like a switch and enable the transferred genes to be expressed (i.e. to give rise to a protein product) in a plant cell. The routine use of these viral promoters is often confused with research which has shown that plant virus genes, which have been transferred into plants to render them virus-resistant, may recombine with related plant viruses that subsequently infect the plant, creating new viral variants. This research demonstrates that there may be a greater risk to the environment if viral genes are transferred to plants because it may lead to the generation of

new plant virus variants capable of infecting a broader range of plants. This is a matter that will be addressed by the Genetic Manipulation Advisory Committee (GMAC) on a case-by-case basis when it assesses such plants.

However, the presence of plant viruses, plant virus genes or plant virus segments in food is not considered to pose any greater risk to human health as plant viruses are ubiquitous in nature and are commonly found in food eaten by animals and humans. Plant viruses are also biologically incapable of naturally infecting human or animal cells.

## **9. Labelling of foods produced using gene technology**

A majority of submissions focussed on this issue. Specifically, the submissions called for the labelling of all foods produced using gene technology, regardless of whether they are substantially equivalent to conventional foods. The submitters based their demands for full labelling on the presumption that all foods produced using gene technology are unsafe and on consumer “right to know” arguments. It was stated that full labelling was the only means of identification of foods produced using gene technology available to consumers.

### *Evaluation*

The existing Standard A18 already makes provision for mandatory labelling of genetically modified foods that are substantially different from their conventional counterparts. However, ANZFA is committed to implementing the in-principle decision of ANZFS Health Ministers of August 1999 to require labelling of all genetically modified foods, including those that are substantially equivalent in composition to the unmodified form. In conjunction with a task force of officials from State and Territory Health Departments and the New Zealand Ministry of Health, ANZFA developed draft revision to Standard A18 in October 1999 that requires labelling of other categories of genetically modified foods. At the Ministers request this draft was circulated for public review and a cost-benefit analysis of full labelling was commissioned. The task force considered both public comments and the cost-benefit analysis in finalising their recommendations to Ministers, which were delivered in May 2000. Ministers are to meet to resolve the issue in July 2000 following whole-of-government consideration of the issue. It is therefore expected that, following a decision and legal amendments to the standard, labelling requirements will be implemented that will apply to all current and subsequent applications.

## **10. The need for post marketing surveillance of genetically modified foods**

A number of submitters have commented on the need for post-market surveillance of genetically modified food consumption.

### *Evaluation*

Surveillance of potential adverse or beneficial effects of GM foods is seen by many as a logical follow-up to the initial scientific risk assessment. Nevertheless, it is recognised that there are limitations to the application of epidemiology studies, particularly in relation to food components. A key requirement for post-market surveillance systems is that a clear hypothesis be identified for testing. Establishing a system for the surveillance of potential health effects of exposure to novel foods requires monitoring of the consumption patterns of novel foods in the population, and health effects in both “exposed” and “non-exposed” individuals/populations,

so that risk estimates can be derived. For any such monitoring system to be useful, there needs to be a range of exposures, otherwise, any variation in health outcome would be unexplainable by that exposure. Variations in exposure could be apparent over time (temporal trends), space (geographical trends) or both.

Availability of robust data on consumption of the foods in question is vital in order to establish a surveillance system. The other side of the equation is the need for access to data on population health outcomes. Such a system could also be used to identify potential positive health outcomes, such as improved nutritional status or lower cholesterol levels. The availability of linked basic data (e.g. date of birth, sex, geographical location), and the ability to correlate with demographic data, could potentially offer the means of establishing links with food consumption.

The possibility of setting up a post-market health surveillance system for novel foods, including GM foods, has been examined by the UK's Advisory Committee on Novel Foods and Processes (ACNFP). Recognising the many difficulties involved in developing such a system, an initial feasibility study to look at the available data and its usefulness has been proposed. Work is currently being commissioned; when completed in 18 months, it will be subject to peer review. If such a feasibility study suggests that post-market surveillance is practical, methods and details concerning data collection will be determined in the UK, but common strategies might be able to be harmonised internationally in order to minimise the use of resources while maximising the reliability of the final results. This is an area that ANZFA will be monitoring closely, along with international regulatory bodies such as the OECD Taskforce for the Safety of Novel Foods and Feeds.

## **11. Public consultation and information about gene technology**

A number of submitters were concerned that the public has not been properly consulted or informed by government or ANZFA on the introduction of foods produced using gene technology. Some submitters urged to undertake wider consultation with all affected parties including growers, the food industry and consumers before these food commodities are introduced, and to ensure that adequate consultation is undertaken as part of its assessment process.

### *Evaluation*

The issue of gene technology and its use in food has been under consideration in Australia since 1992. The Agreement between the Governments of Australia and New Zealand for a joint food standard setting system, however, did not occur until 1995, and the New Zealand community therefore had not been consulted on this matter by the Authority until after that time. Consequently, the proposed standard (the current Standard A18) underwent only one round of public comment in New Zealand at which time significant objections were raised by the New Zealand community to the use of gene technology in food production. Many New Zealand consumers, both in these submissions, and in previous submissions to the Authority, have expressed the view that there has been insufficient consultation and a consistent lack of information about gene technology.

Although Standard A18 came into force in May 1999, the public have a continuous and ongoing opportunity to provide comment in relation to applications under the standard. ANZFA's statutory process for all applications to amend the *Food Standards Code* normally

involves two rounds of public comment. Furthermore, all the documentation (except for commercial in confidence information) relating to these applications is available in the public domain, including the safety assessment reports. There is ample evidence that the provision of such information by ANZFA has already significantly stimulated public debate on this matter.

In addition, other government departments including the Environmental Risk Management Authority (ERMA), are potential sources of information about gene technology available to consumers in New Zealand. ERMA is a statutory authority set up by the New Zealand Government to administer the *Hazardous Substances and New Organisms (HSNO) Act 1996*, and has responsibility for assessing the risks to the environment from genetically modified organisms. This body has been assessing applications for the approval of genetically modified organisms since July 1998 and this has involved a number of public meetings.

In response to the concerns raised in public submissions with regard to gene technology and GM foods, ANZFA is in the process of preparing a public discussion paper on the safety assessment process for GM foods. This will be widely available and may assist in addressing some of the concerns raised by the public. Other government and industry bodies are also addressing the broader concerns in relation to gene technology.

## **12. Maori beliefs and values**

Some New Zealand submitters stated that Maori people find genetic engineering in conflict with their beliefs and values and that, out of respect to Maori, no genetically modified foods should be allowed into New Zealand until a wider discussion, both within Maori and non-Maori, is held.

### *Evaluation*

This issue was also raised during consideration of the proposal for the establishment of Standard A18. At that time, it was stated that the likely implications for Maori regarding genetically modified organisms surround the issues of the rights of Maori to the genetic material from flora and fauna indigenous to New Zealand and the release into the environment of genetically modified organisms. The *HSNO Act 1996* requires that these matters be considered by ERMA.

## **13. Environmental concerns and the broader regulatory framework**

A number of submitters have raised concerns that genetically modified crops may pose a risk to the environment.

### *Evaluation*

These issues are considered in the assessment processes of GMAC in Australia and the Environmental Risk Management Authority (ERMA) in New Zealand. The Authority does not have the mandate to assess matters relating to environmental risks resulting from the release of food produced using gene technology into the environment. However, links exist between ANZFA and other regulatory agencies in both Australia and New Zealand, and a large degree of information sharing occurs. ANZFA would not recommend the approval of a food produced using gene technology if the genetically modified organism from which it was

derived did not have the appropriate clearance for general release from either GMAC (or its successor) or ERMA, as appropriate.

The regulatory system in Australia will comprise the existing regulators with a legal remit to cover some aspects of GM products (such as imports, food, agricultural and veterinary chemicals):

- the Australia New Zealand Food Authority (ANZFA)
- the Therapeutic Goods Administration (TGA)
- the National Registration Authority for Agricultural and Veterinary Chemicals (NRA)
- the National Industrial Chemicals Notification and Assessment Scheme (NICNAS)
- the Australian Quarantine and Inspection Service (AQIS).

Similarly, various other departments and agencies play their role in the regulatory process in New Zealand:

- the Ministry of Agriculture and Fisheries (MAF)
- the Ministry of Health (MoH)
- the Ministry of Research, Science and Technology (MoRST)

In Australia a new Office of the Gene Technology Regulator (OGTR) will complement the existing arrangements. OGTR will supersede the existing arrangements under the Genetic Manipulation Advisory Committee (GMAC), which advises on research and environmental release of GMOs. OGTR will regulate all GMOs and any 'gap' products (i.e. products for which no other regulator has responsibility).

All GM food is assessed and regulated by the Australia New Zealand Food Authority (ANZFA) under the direction of Commonwealth, State and Territories Health Ministers and the New Zealand Health Minister, sitting as Australia New Zealand Food Standards Council (ANZFSC).

There will be an interface between ANZFA and OGTR. Consequential amendments proposed to the ANZFA Act arising from the draft Gene Technology Bill 2000 will establish a statutory interface between OGTR and ANZFA. This will involve amendments to the ANZFA Act requiring the Authority to advise OGTR of recommendations to ANZFSC regarding the standard for foods produced using gene technology (currently Standard A 18).

#### **14. Maximum residue levels**

A number of submitters have raised concerns that residues of agricultural and veterinary chemicals in genetically modified (e.g. herbicide tolerant) crops may pose a health risk.

##### *Evaluation*

Residues of these chemicals can only legally be present if the chemical has been registered for use in Australia and/or New Zealand, and it has been demonstrated that the residue at specified levels does not lead to adverse health impacts. The concentration of a chemical residue that may be present in a food is regulated through maximum residue limits (MRLs). The MRL is the highest residue concentration that is legally permitted in the food. Food products have to meet the MRL, whether or not they are derived from genetically modified organisms. The

MRL does not indicate the chemical residue level that is always present in a food, but it does indicate the highest residue level that could result from the registered conditions of use.

It is important to note that MRLs are not direct public health and safety limits but rather, are primarily indicators of appropriate chemical usage. MRLs are always set at levels lower than, and normally very much lower than, the health and safety limits. The MRL is determined following a comprehensive evaluation of scientific studies on chemistry, metabolism, analytical methods and residue levels. In Australia, the National Registration Authority (NRA) applies to ANZFA to amend the MRLs in the Food Standards Code and the application is considered by ANZFA through its legislated decision making processes. In New Zealand MRLs are set by the Ministry of Health, generally following a request from, and in collaboration with, the Ministry of Agriculture and Forestry. Only following demonstration that the use of agricultural and veterinary chemicals will not result in unsafe residues will the MRL enter into food law through its inclusion in either the Food Standards Code in Australia, or the New Zealand (Maximum Residue Limits of Agricultural Compounds) Mandatory Food Standard 1999.